Digestive system disorder
MONDO:0004335A disease or disorder that involves the digestive system.
Also known as: digestive disease, digestive system disease, digestive system disease or disorder, digestive system disorder, disease of digestive system, disease or disorder of digestive system, disorder of digestive system, gastroenterological system disease
17049 clinical trials for this condition and its sub-types, 173 tagged with Digestive system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Digestive system disorder
-
Digestive system cancer 273 trials · 7,342 incl. sub-types
15 sub-types
- Digestive system carcinoma 25 trials · 5,085 incl. sub-types Sub-types →
- Intestinal cancer 25 trials · 2,906 incl. sub-types Sub-types →
- Liver cancer 265 trials · 1,779 incl. sub-types Sub-types →
- Malignant pancreatic neoplasm 929 trials · 1,499 incl. sub-types Sub-types →
- Gastric cancer 748 trials · 1,073 incl. sub-types Sub-types →
- Esophageal cancer 415 trials · 812 incl. sub-types Sub-types →
- Pharynx cancer 12 trials · 512 incl. sub-types Sub-types →
- Oral cavity cancer 44 trials · 299 incl. sub-types Sub-types →
- Gastroesophageal cancer 159 trials
- Gallbladder cancer 80 trials · 115 incl. sub-types Sub-types →
- Gastrointestinal lymphoma 0 trials · 8 incl. sub-types Sub-types →
- Jaw cancer 1 trial · 5 incl. sub-types Sub-types →
- Spleen cancer 0 trials · 3 incl. sub-types Sub-types →
- Digestive system melanoma 0 trials · 2 incl. sub-types Sub-types →
- Malignant tumor of floor of mouth 0 trials · 2 incl. sub-types Sub-types →
-
Pancreas disorder 46 trials · 5,855 incl. sub-types
14 sub-types
- Endocrine pancreas disorder 1 trial · 4,130 incl. sub-types Sub-types →
- Pancreatic neoplasm 960 trials · 1,635 incl. sub-types Sub-types →
- Pancreatitis 124 trials · 212 incl. sub-types Sub-types →
- Exocrine pancreatic insufficiency 30 trials Sub-types →
- Recurrent acute pancreatitis 20 trials
- Accessory pancreas 0 trials
- Acinar cystic transformation of the pancreas 0 trials
- Annular pancreas 0 trials
- Congenital pancreatic cyst 0 trials
- Follicular cholangitis and pancreatitis 0 trials
- Lymphoepithelial cyst of the pancreas 0 trials
- Pancreatic mucinous ductal ectasia 0 trials
- Pancreatic steatorrhea 0 trials
- Pancreatic triacylglycerol lipase deficiency 0 trials Sub-types →
-
Intestinal disorder 70 trials · 5,671 incl. sub-types
58 sub-types
- Large intestine disorder 2 trials · 3,992 incl. sub-types Sub-types →
- Intestinal neoplasm 4 trials · 3,202 incl. sub-types Sub-types →
- Inflammatory bowel disease 456 trials · 1,130 incl. sub-types Sub-types →
- Gastroenteritis 22 trials · 889 incl. sub-types Sub-types →
- Small intestine disorder 7 trials · 403 incl. sub-types Sub-types →
- Irritable bowel syndrome 233 trials
- Bowel dysfunction 11 trials · 221 incl. sub-types Sub-types →
- Glucose-galactose malabsorption 2 trials · 162 incl. sub-types Sub-types →
- Malabsorption syndrome 13 trials · 125 incl. sub-types Sub-types →
- Intestinal obstruction 47 trials · 95 incl. sub-types Sub-types →
- Eosinophilic gastrointestinal disease 9 trials · 73 incl. sub-types Sub-types →
- Intestinal fistula 6 trials · 66 incl. sub-types Sub-types →
- Necrotizing enterocolitis 51 trials Sub-types →
- Short bowel syndrome 41 trials Sub-types →
- Intestinal motility disease 10 trials · 39 incl. sub-types Sub-types →
- Diverticulitis 29 trials · 35 incl. sub-types Sub-types →
- Chronic intestinal failure 24 trials
- Neurogenic bowel 22 trials
- Postgastrectomy syndrome 2 trials · 21 incl. sub-types Sub-types →
- Hypertrophic pyloric stenosis 17 trials Sub-types →
- Ischemic bowel disorder 8 trials · 16 incl. sub-types Sub-types →
- Parasitic intestinal disorder 0 trials · 16 incl. sub-types Sub-types →
- Endometriosis of intestine 9 trials
- Intestinal perforation 9 trials Sub-types →
- Intestinal polyp 8 trials
- Protein-losing enteropathy 7 trials
- Intestinal atresia 3 trials · 6 incl. sub-types Sub-types →
- Chronic intestinal vascular insufficiency 4 trials
- Refractory celiac disease 4 trials
- Volvulus of midgut 4 trials Sub-types →
- Abetalipoproteinemia 2 trials
- Pneumatosis cystoides intestinalis 2 trials
- Angiodysplasia of intestine 1 trial
- Chronic enteropathy associated with SLCO2A1 gene 1 trial
- Cryptogenic multifocal ulcerous stenosing enteritis 1 trial
- Steatorrhea 1 trial Sub-types →
- 4-hydroxyphenylacetic aciduria 0 trials
- Aeromonas hydrophila intestinal disease 0 trials
- NK-cell enteropathy 0 trials
- Satoyoshi syndrome 0 trials
- Whipple disease 0 trials
- Aplasia cutis congenita-intestinal lymphangiectasia syndrome 0 trials
- Chronic atrial and intestinal dysrhythmia 0 trials
- Chronic diarrhea with villous atrophy 0 trials
- Collagenous sprue 0 trials
- Congenital diarrhea 7 with exudative enteropathy 0 trials
- Congenital enterocyte heparan sulfate deficiency 0 trials
- Cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder 0 trials
- Intestinal dysmotility syndrome 0 trials
- Intestinal lymphangiectasia 0 trials Sub-types →
- Intractable diarrhea-choanal atresia-eye anomalies syndrome 0 trials
- Isolated mesenteric vein thrombosis 0 trials
- Malakoplakia 0 trials
- Mucocele of appendix 0 trials
- Primary desmosis coli 0 trials
- Solitary rectal ulcer syndrome 0 trials
- Trichohepatoenteric syndrome 0 trials Sub-types →
- Visceral leiomyopathy, African degenerative 0 trials
-
Hepatobiliary disorder 10 trials · 4,086 incl. sub-types
4 sub-types
- Liver disorder 338 trials · 3,785 incl. sub-types Sub-types →
- Hepatobiliary neoplasm 26 trials · 1,853 incl. sub-types Sub-types →
- Biliary tract disorder 22 trials · 1,044 incl. sub-types Sub-types →
- Gallbladder disorder 27 trials · 234 incl. sub-types Sub-types →
-
Stomach disorder 4 trials · 1,692 incl. sub-types
19 sub-types
- Gastric neoplasm 715 trials · 1,144 incl. sub-types Sub-types →
- Gastroesophageal reflux disease 230 trials Sub-types →
- Functional gastric disease 50 trials · 222 incl. sub-types Sub-types →
- Gastritis 21 trials · 53 incl. sub-types Sub-types →
- Hiatus hernia 52 trials Sub-types →
- Pyloric stenosis 15 trials · 32 incl. sub-types Sub-types →
- Gastric intestinal metaplasia 21 trials
- Gastric ulcer 13 trials Sub-types →
- Stomach polyp 4 trials · 6 incl. sub-types Sub-types →
- Gastric dilatation 3 trials
- Achlorhydria 1 trial
- Pylorospasm 1 trial
- Dieulafoy lesion 0 trials
- Angiodysplasia of stomach 0 trials
- Cascade stomach 0 trials
- Gastric duplication 0 trials
- Non-hypoproteinemic hypertrophic gastropathy 0 trials
- Pyloric duplication 0 trials
- Stomach diverticulosis 0 trials
-
Upper digestive tract disorder 6 trials · 1,270 incl. sub-types
2 sub-types
- Esophageal disorder 20 trials · 1,265 incl. sub-types Sub-types →
- Internal hirudiniasis 0 trials
-
Autoimmune disorder of gastrointestinal tract 0 trials · 993 incl. sub-types
7 sub-types
- Type 1 diabetes mellitus 865 trials · 866 incl. sub-types Sub-types →
- Celiac disease 85 trials Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune enteropathy 2 trials · 11 incl. sub-types Sub-types →
- Autoimmune pancreatitis 5 trials Sub-types →
- Autoimmune gastritis 3 trials
- IgG4-related sclerosing cholangitis 0 trials
-
Digestive system infectious disorder 4 trials · 639 incl. sub-types
22 sub-types
- Viral hepatitis 12 trials · 471 incl. sub-types Sub-types →
- Infectious colitis 0 trials · 72 incl. sub-types Sub-types →
- Intestinal infectious disease 4 trials · 51 incl. sub-types Sub-types →
- Small intestinal bacterial overgrowth 19 trials
- Parasitic intestinal disorder 0 trials · 16 incl. sub-types Sub-types →
- Liver abscess (disease) 4 trials
- Campylobacteriosis 3 trials Sub-types →
- Bacterial gastritis 2 trials
- Gastrointestinal tuberculosis 0 trials · 2 incl. sub-types Sub-types →
- Aeromonas hydrophila intestinal disease 0 trials
- Salmonella gastroenteritis 0 trials
- Whipple disease 0 trials
- Anal verrucous carcinoma 0 trials
- Bacterial esophagitis 0 trials
- Colorectal Kaposi sarcoma 0 trials Sub-types →
- Fungal esophagitis 0 trials Sub-types →
- Fungal gastritis 0 trials
- Internal hirudiniasis 0 trials
- Oropharyngeal anthrax 0 trials
- Polycystic echinococcosis 0 trials
- Viral esophagitis 0 trials
- Viral gastritis 0 trials Sub-types →
-
Neoplasm of oropharynx 3 trials · 289 incl. sub-types
2 sub-types
- Oropharynx cancer 153 trials · 289 incl. sub-types Sub-types →
- Benign neoplasm of oropharynx 0 trials
-
Digestive system neuroendocrine neoplasm 54 trials · 172 incl. sub-types
7 sub-types
- Digestive system neuroendocrine tumor, grade 1/2 68 trials · 150 incl. sub-types Sub-types →
- Pancreatic neuroendocrine neoplasm 10 trials · 87 incl. sub-types Sub-types →
- Intestinal neuroendocrine neoplasm 7 trials · 22 incl. sub-types Sub-types →
- Gastric neuroendocrine neoplasm 3 trials · 6 incl. sub-types Sub-types →
- Liver neuroendocrine carcinoma 3 trials Sub-types →
- Gallbladder neuroendocrine neoplasm 0 trials Sub-types →
- Salivary gland small cell carcinoma 0 trials
-
Diarrheal disease 85 trials · 123 incl. sub-types
7 sub-types
- Acute diarrhea 12 trials · 44 incl. sub-types Sub-types →
- Inflammatory diarrhea 0 trials · 33 incl. sub-types Sub-types →
- Chronic diarrheal disease 10 trials Sub-types →
- Congenital diarrhea 0 trials · 5 incl. sub-types Sub-types →
- Secretory diarrhea 0 trials · 5 incl. sub-types Sub-types →
- Diarrheal disease secondary to altered bowel motility 0 trials Sub-types →
- Non-infectious diarrheal disease 0 trials Sub-types →
-
Peptic ulcer disease 26 trials · 68 incl. sub-types
6 sub-types
- Peptic esophagitis 25 trials
- Gastric ulcer 13 trials Sub-types →
- Duodenal ulcer 7 trials
- Gastrojejunal ulcer 6 trials
- Active peptic ulcer disease 3 trials
- Peptic ulcer perforation 3 trials
-
Gastrointestinal mucositis 3 trials · 54 incl. sub-types
2 sub-types
- Intestinal infectious disease 4 trials · 51 incl. sub-types Sub-types →
- Inflammatory diarrhea 0 trials · 33 incl. sub-types Sub-types →
-
Benign digestive system neoplasm 0 trials · 41 incl. sub-types
10 sub-types
- Pleomorphic adenoma 12 trials
- Hepatobiliary benign neoplasm 2 trials · 8 incl. sub-types Sub-types →
- Benign neoplasm of pancreas 7 trials Sub-types →
- Intestinal benign neoplasm 1 trial · 7 incl. sub-types Sub-types →
- Benign neoplasm of esophagus 3 trials Sub-types →
- Benign neoplasm of stomach 1 trial · 2 incl. sub-types Sub-types →
- Hepatocellular adenoma 2 trials Sub-types →
- Benign neoplasm of gallbladder 0 trials Sub-types →
- Benign neoplasm of oropharynx 0 trials
- Bile duct papillary neoplasm 0 trials Sub-types →
-
Hereditary mixed polyposis syndrome 5 trials · 6 incl. sub-types
2 sub-types
-
Juvenile polyposis syndrome 5 trials
3 sub-types
-
Gastrointestinal polyp 0 trials · 3 incl. sub-types
2 sub-types
- Gastrointestinal hamartoma 0 trials · 3 incl. sub-types Sub-types →
- Anal polyp 0 trials Sub-types →
-
Cronkhite-Canada syndrome 1 trial
-
Hyperplastic polyposis syndrome 1 trial
2 sub-types
- Colon serrated polyposis 1 trial
- Sessile serrated polyposis cancer syndrome 0 trials
-
Meckel diverticulum 0 trials
-
Caudal duplication 0 trials
-
Common mesentery 0 trials
-
Congenital peritoneal encapsulation 0 trials
-
Digestive duplication 0 trials
-
Diverticulosis, small-intestinal 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 6392 trials in this tab.
-
New liver, new chance: transplant tested against inoperable bile duct cancer
Cure Recruiting nowResearchers at Oslo University Hospital are testing whether a liver transplant can help people with perihilar cholangiocarcinoma, a bile duct cancer that cannot be removed with standard surgery. The trial enrolls about 15 participants who have no signs of cancer spread beyond the…
Sponsor: Oslo University Hospital • Aim: Cure
Last updated Oct 17, 2026 08:00 UTC
-
Gut bacteria swap tested against stubborn c. diff infections
Cure Recruiting nowResearchers at Aarhus University Hospital are tracking adults with recurrent Clostridioides difficile infection who receive fecal microbiota transplantation, a treatment that moves stool from a screened donor into the patient's gut. Donor material is delivered by colonoscopy, a t…
Sponsor: University of Aarhus • Aim: Cure
Last updated Oct 17, 2026 08:00 UTC
-
Pfizer launches massive trial of c. diff vaccine for seniors
Vaccine Recruiting nowThis study tests whether a vaccine can prevent C. difficile infection in adults 65 and older. About 32,000 participants will receive either the vaccine or a placebo shot. The study will track infections and side effects over up to three and a half years.
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Oct 15, 2026 00:00 UTC
-
New hope for Crohn's: phase 3 trial of afimkibart launches
Disease control Recruiting nowThis phase 3 study tests a drug called afimkibart in 600 people with moderate-to-severe Crohn's disease. Participants receive either the drug or a placebo to see if it can reduce symptoms and gut inflammation. The trial is double-blind, meaning neither patients nor doctors know w…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New shortcut for blood pressure treatment?
Disease control Recruiting nowThis study tests a faster version of a procedure called renal denervation, which uses energy to calm overactive nerves in the kidneys to lower blood pressure. About 130 adults with uncontrolled high blood pressure will receive the quicker procedure. The goal is to see if it works…
Sponsor: Medtronic Vascular • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New pill aims to break the cycle of repeat c. diff infections
Disease control Recruiting nowThis phase 2 trial tests an oral drug called ibezapolstat in 20 people who have had three or more C. diff infections in the past year. The goal is to see if the drug can cure the current infection and reduce the chance of it coming back. Participants will take the drug twice a da…
Phase 2 • Sponsor: Acurx Pharmaceuticals Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a new Weight-Loss drug replace semaglutide safely?
Disease control Recruiting nowResearchers are testing how well people with overweight or obesity, with or without type 2 diabetes, tolerate switching from semaglutide to an experimental drug called zenagamtide. All 60 participants receive both drugs as injections. The study measures side effects and how the b…
Phase 1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug combo aims to shrink Hard-to-Treat neuroendocrine tumors
Disease control Recruiting nowThis study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a new drug combo shrink metastatic colorectal tumors?
Disease control Recruiting nowThis trial tests whether an experimental drug called LBL-024, when combined with standard treatments like bevacizumab, oxaliplatin, capecitabine, or fruquintinib, can safely shrink tumors in people with metastatic colorectal cancer. The study includes adults aged 18 to 75 who hav…
Phase 1/2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New ultrasound device aims to speed up dialysis access healing
Disease control Recruiting nowThis study tests a device called EchoMark/EchoSure that is implanted during fistula surgery for dialysis patients. The device uses automated ultrasound to monitor healing every two weeks. The goal is to see if it helps the fistula mature faster and reduces the need for additional…
Sponsor: Sonavex, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Tighter blood sugar targets during pregnancy: could they protect newborns?
Disease control Recruiting nowThis study compares two blood sugar targets for overweight or obese women with gestational diabetes. One group aims for stricter goals (fasting under 90 mg/dL, after meals under 120 mg/dL), while the other follows standard targets (fasting under 95 mg/dL, after meals under 140 mg…
Sponsor: Indiana University • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
One operation or two? trial tests best timing for colorectal cancer and liver metastasis surgery
Disease control Recruiting nowResearchers compare two surgical approaches for patients whose colorectal cancer has spread to the liver. In one approach, surgeons remove the colon tumor and liver metastases in a single operation. In the other, they perform two separate operations within 4 to 12 weeks. The tria…
Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for ulcerative colitis: Long-Term remission trial begins
Disease control Recruiting nowThis study tests an investigational drug called duvakitug in people with moderate-to-severe ulcerative colitis who have already responded to treatment. The goal is to see if duvakitug can help maintain remission better than a placebo over 40 weeks, with an optional long-term exte…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Second dose of targeted radiation may outperform standard drugs for stubborn gut tumors
Disease control Recruiting nowThis study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a specialized clinic reverse heart risks in diabetes?
Disease control Recruiting nowResearchers test whether a specialized cardiometabolic clinic can improve heart function and reduce coronary inflammation in people with type 2 diabetes and established cardiovascular disease. Participants are randomly assigned to the clinic or usual care. The clinic provides ind…
Sponsor: Odense University Hospital • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…
Phase 1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a drug cocktail save Insulin-Making cells in newly diagnosed kids?
Disease control Recruiting nowThis study tests whether giving a low dose of anti-thymocyte globulin (ATG) followed by either adalimumab or verapamil can help preserve the body's ability to make insulin in people aged 9 to under 21 who were recently diagnosed with type 1 diabetes. The main goal is to see if th…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Engineered immune cells take on tough cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…
Phase 1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Radioactive missile aims at Cancer's c-MET switch
Disease control Recruiting nowResearchers are testing a new targeted radioligand therapy called [225Ac]Ac-FL-261 in people with advanced solid tumors that overexpress a protein called c-MET. The therapy pairs a radioactive particle with a molecule that seeks out c-MET, aiming to deliver radiation directly to …
Phase 1/2 • Sponsor: Full-Life Technologies UK Limited • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Virtual care for chronic diseases: can teleconsultation replace clinic visits for older adults?
Disease control Recruiting nowResearchers are testing a teleconsultation care pathway for older adults with hypertension, diabetes, and dyslipidemia at a primary care clinic in Kuala Lumpur, Malaysia. The study compares virtual visits with usual in-person care to see if the virtual approach is feasible and co…
Sponsor: National University of Malaysia • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for stomach cancer: phase 3 trial tests rilvegostomig combo
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug called rilvegostomig, combined with trastuzumab deruxtecan and chemotherapy, works better than the current standard treatment for HER2-positive stomach cancer that has spread. About 840 people whose tumors have a specific protein (…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for liver metastases: immune booster combined with targeted chemo
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Could a cancer drug slow bile duct tumors?
Disease control Recruiting nowThis study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New 4-Drug cocktail aims to fight tough colorectal cancer
Disease control Recruiting nowThis study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if the combination can shrink tumors and improve …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
One pill for two conditions: blood pressure and blood sugar in the crosshairs
Disease control Recruiting nowResearchers are testing whether a once-daily combination pill can lower both blood pressure and blood sugar in people who have essential hypertension and type 2 diabetes. The phase 3 trial enrolls about 276 adults who stop their existing blood pressure and diabetes medicines, exc…
Phase 3 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New antibody combo takes on tough colorectal cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called EMB-01, a bispecific antibody that targets two cancer-related proteins, combined with standard chemotherapy. About 120 adults with advanced colorectal cancer that cannot be surgically removed will receive the combination. The main go…
Phase 1 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a home light device fight gum disease and help diabetes?
Disease control Recruiting nowResearchers are testing whether a home-use antibacterial light device, used alongside normal brushing and flossing, can reduce gum bleeding and plaque in people with type 2 diabetes or pre-diabetes. The trial enrolls 150 adults with at least 20 teeth who get dental care through c…
Sponsor: Wellbeing Services County of Pirkanmaa • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Smart drug targets two cancer weaknesses at once
Disease control Recruiting nowThis trial tests a new drug called AN4035 in people with advanced solid tumors that have RAS mutations and high levels of the CEACAM5 protein. The drug is designed to seek out cancer cells carrying CEACAM5 and deliver a payload that blocks RAS, a key driver of cancer growth. The …
Phase 1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug aims to tame autoimmune hepatitis and cut steroid use
Disease control Recruiting nowThis study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive e…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a website and a buddy help tame diabetes? large trial puts it to the test.
Disease control Recruiting nowThis study tests whether helping people with diabetes find local resources (like food or housing help) and pairing them with a peer supporter can improve blood sugar and blood pressure. About 694 adults with diabetes who have trouble controlling their condition will be randomly a…
Sponsor: University of Michigan • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Psoriasis drug may be safe for patients with fatty liver
Disease control Recruiting nowThis study looks at how long adults with plaque psoriasis and a common liver condition called MASLD (fatty liver disease) continue taking the drug secukinumab. Researchers will review medical records from several Spanish hospitals to track treatment duration and changes in liver …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can surgery after drug therapy beat drugs alone for stomach cancer spread?
Disease control Recruiting nowThis trial tests whether adding radical surgery to remove the stomach tumor and nearby lymph nodes improves survival and quality of life compared with continuing drug therapy alone in patients with stomach cancer that has spread to the abdominal lining (peritoneal metastasis) and…
Phase 3 • Sponsor: Hua Huang, MD, PhD • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Could immunotherapy spare throat cancer patients from losing their voice?
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced laryngeal or hypopharyngeal cancer avoid having their voice box removed. The study will enroll 87 adults whose cancer has not been treated before…
Phase 2 • Sponsor: Matthew Spector • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New immunotherapy combo takes on advanced colorectal cancer
Disease control Recruiting nowThis trial tests a new immunotherapy called STC-1010 combined with standard chemotherapy and immune boosters in people with advanced colorectal cancer that cannot be removed by surgery. The study has two parts: first, finding the safest dose in about 21-33 participants, then test…
Phase 1/2 • Sponsor: Brenus Pharma • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New cocktail of drugs could shrink stomach tumors before surgery
Disease control Recruiting nowThis study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: phase 3 trial launches
Disease control Recruiting nowThis Phase 3 study tests a new drug, telisotuzumab adizutecan, combined with bevacizumab, against the standard treatment (LONSURF plus bevacizumab) in 700 adults with advanced colorectal cancer that has stopped responding to prior therapies. The goal is to see if the new combo sh…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug LTZ-232 tested against Hard-to-Treat colorectal cancer
Disease control Recruiting nowResearchers are running a first-in-human Phase 1/1b trial of LTZ-232, an intravenous drug given every two weeks for up to 24 months. The study enrolls adults with advanced or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments. The m…
Phase 1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New vaccine could help throat cancer patients avoid radiation
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer, potentially allowing them to skip radiation. About 70 adults will receive either chemo alone or che…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Could adding common diabetes pills improve type 1 control?
Disease control Recruiting nowThis study looks at whether adding GLP-1 receptor agonists or SGLT inhibitors to insulin helps adults with type 1 diabetes manage their blood sugar better. Researchers will track 300 participants for one year, measuring changes in HbA1c and other health markers. The goal is to se…
Sponsor: Indiana University • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The study includes 38 adults with advanced solid tumors, such as liver cancer, who have not responde…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for bile duct cancer: experimental combo targets tough tumors
Disease control Recruiting nowThis study tests a new drug (CDX-1140) combined with three other cancer drugs for people with advanced biliary tract cancer that has spread or come back after treatment. About 60 adults will receive the drugs through an IV and a pill over 21-day cycles for up to 2 years. The goal…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for minority patients with hard-to-treat stomach and esophageal cancers
Disease control Recruiting nowThis study is testing a drug called tislelizumab combined with chemotherapy as a first treatment for people with advanced stomach or esophageal cancer that cannot be removed by surgery or has spread. It focuses on racial and ethnic minority groups in the US, including Black, Hisp…
Phase 2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New targeted therapy combo aims to fight stubborn stomach cancers
Disease control Recruiting nowThis Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug targets cancer spread in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug cocktail targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The goal is to find the safest dose and see if the combination can slow or stop tumor growth. About 92 participants wi…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for advanced esophageal cancer: combo therapy trial launches
Disease control Recruiting nowThis study tests new drug combinations (including an antibody-drug conjugate) with the immunotherapy pembrolizumab, with or without chemotherapy, for people with advanced esophageal cancer that cannot be removed by surgery or has spread. About 298 participants will join to see if…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New pill plus chemo aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…
Phase 3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New triplet therapy hopes to shrink liver tumors
Disease control Recruiting nowThis study tests a combination of three drugs (atezolizumab, bevacizumab, and memantine) in 19 adults with advanced liver cancer that cannot be removed by surgery. The main goal is to see how many patients have their tumors shrink or disappear. Participants must be newly diagnose…
Phase 2 • Sponsor: Inova Health Care Services • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New radioactive drug targets Hard-to-Treat gut and adrenal tumors
Disease control Recruiting nowThis study tests a new radioactive drug, [212Pb]VMT-alpha-NET, in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paragangliomas that have already been treated with radiation therapy. The drug is designed to attach to a protein on the surface of th…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New hope for kids with colitis: risankizumab trial launches
Disease control Recruiting nowThis phase 3 study tests the drug risankizumab in about 120 children aged 2 to 18 with moderate to severe ulcerative colitis. The trial has three parts: an initial 12-week IV treatment period, a 52-week maintenance phase where patients get one of two doses by injection, and a lon…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New drug AVZO-1418 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.
Phase 1/2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Could a simple algorithm help doctors write better exercise prescriptions?
Disease control Recruiting nowThis study tests a new digital tool called P3-EX that helps doctors create personalized exercise plans for patients with heart disease risk factors like high blood pressure, diabetes, and obesity. Researchers will recruit 24 doctors and 48 patients to compare the new tool with a …
Sponsor: University of Connecticut • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New pill targets KRAS mutations in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …
Phase 1/2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Could less be more? new study tests lower doses of cancer drug
Disease control Recruiting nowThis study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New program aims to transform diabetes treatment in nigeria
Disease control Recruiting nowThis study will test a program based on WHO guidelines to improve diabetes screening and care in 10 primary health centers in Nigeria. About 2,800 adults with or at risk for diabetes will take part. The goal is to see if the program helps more people get diagnosed and treated.
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can MASH drug rezdiffra share the medicine cabinet with diabetes pills?
Disease control Recruiting nowResearchers are studying whether Rezdiffra (resmetirom) can be taken safely alongside two diabetes drugs, pioglitazone and dapagliflozin, in adults who have MASH with moderate to advanced liver fibrosis. The trial enrolls about 150 adults with MASH and liver scarring but no cirrh…
Phase 4 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a pill duo outsmart a Hard-to-Treat pancreatic cancer mutation?
Disease control Recruiting nowThis phase 3 trial compares a combination of two experimental oral drugs, zoldonrasib and daraxonrasib, against standard chemotherapy (gemcitabine plus nab-paclitaxel) as the first treatment for people with metastatic pancreatic cancer that has a specific KRAS G12D mutation. The …
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a new weight-loss drug replace tirzepatide? trial tests the switch
Disease control Recruiting nowResearchers are testing how well people with overweight or obesity, with or without type 2 diabetes, tolerate switching from tirzepatide to a new drug called zenagamtide. The trial aims to find which dose of zenagamtide works best after people have been on a stable dose of tirzep…
Phase 1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Recruiting nowThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
Can a liver drug help patients with fatty liver disease and a stiff heart?
Disease control Recruiting nowResearchers are testing resmetirom, an oral drug, in adults who have metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). The trial assigns participants to receive resmetirom or a placebo for 24 weeks. The main goals …
Phase 1 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Oct 17, 2026 08:00 UTC
-
New combo therapy shows promise for tough bile duct cancer
Disease control Recruiting nowThis Phase 2 trial is testing a combination of paclitaxel polymer micelle and immunotherapy for people with advanced biliary tract cancer whose disease has progressed after standard first-line treatment. The study aims to see if this new drug combo can shrink tumors and control t…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Immunotherapy cocktail takes on tough pancreatic cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug sintilimab to chemotherapy and radiation can help people with inoperable pancreatic cancer live longer. The study will enroll 25 participants who have not had prior treatment. Researchers will track how long the …
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Could an immunotherapy boost help fight stomach cancer?
Disease control Recruiting nowThis clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Glow-and-Kill surgery: new light therapy targets hidden cancer cells
Disease control Recruiting nowThis study tests a two-step approach during surgery for people with advanced or returning colorectal cancer. First, a drug makes cancer cells glow under blue light so surgeons can see and remove them. Then, red laser light activates the drug to kill any remaining cancer cells. Th…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for Crohn's: experimental drug SAR442970 enters phase 2 trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called SAR442970 in about 99 adults with moderate to severe Crohn's disease. Participants will receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug can improve the appearance of the g…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New clip tested in 250 patients to seal gut bleeds and tears
Disease control Recruiting nowThis study tracks how well a device called the DAT clip works during routine endoscopy to stop bleeding, close perforations (holes), or treat fistulas (abnormal connections) in the digestive tract. Researchers will record data from 250 adults who need this clip as part of their s…
Sponsor: AdventHealth • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Could an arthritis drug help fight pancreatic cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug anakinra (Kineret) to standard chemotherapy can improve outcomes for people with pancreatic cancer that can be surgically removed or is locally advanced. Anakinra is an anti-inflammatory drug typically used for rheumatoid arth…
Phase 2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug BNT329 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Can a diabetes drug protect blood vessels in type 1 diabetes?
Disease control Recruiting nowThis phase 2 trial tests whether dulaglutide, a drug used for type 2 diabetes, can improve small blood vessel function in adults with type 1 diabetes. The study involves 47 participants aged 18-40 with long-standing type 1 diabetes. Researchers measure blood flow and insulin sens…
Phase 2 • Sponsor: AdventHealth Translational Research Institute • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill targets Hard-to-Treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…
Phase 1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug combo could boost rectal cancer remission before surgery
Disease control Recruiting nowThis phase 3 trial compares two different oral chemotherapy drugs given alongside radiation before surgery for locally advanced rectal cancer. The standard drug, capecitabine, is being tested against a newer drug called TAS-102. The goal is to see if TAS-102 leads to more tumors …
Phase 3 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Engineered immune cells take on stomach cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing a new type of immunotherapy called CAR T-cells for people with a specific kind of stomach and esophageal cancer that has spread to the lining of the abdomen. The treatment involves collecting a patient's own immune cells, modifying them in a lab …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill targets stubborn colorectal cancer mutation
Disease control Recruiting nowThis study tests an experimental pill called VS-7375, designed to block a specific cancer-driving protein (KRAS G12D). The trial includes people with metastatic colorectal cancer that has this mutation. Some participants receive VS-7375 alone, others get it combined with an antib…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Experimental combo targets Tough-to-Treat colorectal cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs—abemaciclib and 5-fluorouracil—is safe and tolerable for people with advanced colorectal cancer that has spread and stopped responding to standard treatments. About 39 participants will receive the combination to find …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Low-Dose radiation plus immunotherapy shows promise in rectal cancer trial
Disease control Recruiting nowThis study tests a new approach for people with a common type of locally advanced rectal cancer. It combines low-dose radiation with an immunotherapy drug (pucotenlimab) and chemotherapy before surgery. The goal is to see if this combination can make the tumor disappear completel…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New cocktail therapy aims to shrink advanced liver tumors
Disease control Recruiting nowThis study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug combo aims to fight Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining two drugs—fruquintinib and TAS-102—works better than fruquintinib alone for people with advanced colorectal cancer that hasn't responded to prior treatments. About 120 adults will be randomly assigned to one of the two groups. The main g…
Phase 2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Can a second stomach step double the power of Weight-Loss surgery?
Disease control Recruiting nowThis trial tests whether adding a second procedure to a standard weight-loss operation leads to greater weight loss and better metabolic health in adults with obesity. The standard procedure, endoscopic sleeve gastroplasty (ESG), uses stitches to make the stomach smaller. The add…
Sponsor: West Virginia University • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Could Two-Drug cocktails tame stubborn inflammatory bowel disease?
Disease control Recruiting nowThis study tests whether combining risankizumab with either trosunilimab or ABBV-701 can safely reduce inflammation and improve symptoms in adults with moderately to severely active Crohn's disease or ulcerative colitis. Participants are randomly assigned to one of the combinatio…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New liposomal drug takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Could a gut hormone boost islet transplants and free type 1 diabetes patients from insulin shots?
Disease control Recruiting nowThis study tests whether adding a natural gut hormone called gastrin to islet cell transplants can help people with hard-to-control type 1 diabetes produce their own insulin and stabilize blood sugar. About 20 adults aged 18-68 with unstable type 1 diabetes will receive donor isl…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Steroid shield: prednisone may protect liver during cancer radiation
Disease control Recruiting nowThis study tests whether taking prednisone, a steroid, before and during radiation therapy can protect the liver in people with liver cancer. About 20 participants will take prednisone for a short time around their radiation sessions. The goal is to see if it reduces liver inflam…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat colorectal tumors
Disease control Recruiting nowThis study tests an experimental drug called telisotuzumab adizutecan combined with standard chemotherapy in people whose colorectal cancer has spread. The goal is to see if the combination shrinks tumors and is safe. About 390 adults will take part at hospitals worldwide.
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug MDX2001 tested in 285 patients with advanced cancers
Disease control Recruiting nowThis study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…
Phase 1/2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Can stronger radiation tame inoperable rectal cancer without surgery?
Disease control Recruiting nowThis trial investigates whether giving a higher dose of radiotherapy can safely control locally recurrent rectal cancer that cannot be surgically removed. Around 30 adults with this condition will receive either stereotactic body radiotherapy or hyperfractionated chemo-reirradiat…
Sponsor: Heike M.U. Peulen • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug shows promise in reversing liver scarring in major trial
Disease control Recruiting nowThis Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …
Phase 3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Triple therapy shrinks bile duct tumors, may enable surgery
Disease control Recruiting nowThis phase II trial tests a combination of immunotherapy (tislelizumab), chemotherapy (gemcitabine plus cisplatin or oxaliplatin), and targeted radiation before possible surgery in 38 people with hilar cholangiocarcinoma that is borderline or not removable. The goal is to see if …
Phase 2 • Sponsor: Jinbo Yue • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Could some esophageal cancer patients skip surgery? new trial tests a less invasive option
Disease control Recruiting nowThis study looks at two approaches for people with a type of esophageal cancer that shrank after initial chemo-immunotherapy. One group will have surgery to remove the tumor, while the other will get a combination of radiation and chemotherapy instead. Both groups will also recei…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Double immunotherapy may keep nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New combo therapy targets stomach cancer lymph nodes
Disease control Recruiting nowThis phase II trial tests whether adding surgery and radiation to standard chemotherapy can improve outcomes for people with stomach cancer that has spread only to nearby lymph nodes. About 54 participants will receive either standard chemo or a more intensive plan including chem…
Phase 2 • Sponsor: Jinbo Yue • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Can a targeted drug conjugate outsmart advanced colorectal cancer?
Disease control Recruiting nowThis phase 1 trial tests an investigational drug called DEM301 in adults with advanced colorectal cancer that has progressed after standard treatments. DEM301 is an antibody-drug conjugate, a type of therapy designed to deliver a toxic agent directly to cancer cells. The study ai…
Phase 1 • Sponsor: DEM BioPharma, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug XB010 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…
Phase 1 • Sponsor: Exelixis • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug combo enters human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called OMTX705, which targets a protein on cancer cells, combined with standard chemotherapy and an immunotherapy for people with advanced pancreatic cancer that has spread. The study will enroll 69 participants to first find the safes…
Phase 1 • Sponsor: Oncomatryx Biopharma S.L. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Can this IV drug help avoid liver transplants in heavy drinkers?
Disease control Recruiting nowThis Phase 3 trial tests an experimental drug called larsucosterol in 350 people with severe alcohol-associated hepatitis. The goal is to see if the drug helps patients survive for 90 days without needing a liver transplant. Participants receive either the drug or a placebo by IV…
Phase 3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 a…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New cell therapy targets common cancer mutation in early trial
Disease control Recruiting nowThis early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New pill combo aims to shrink Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…
Phase 1/2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can focused radiation boost Immunotherapy's power against advanced cancer?
Disease control Recruiting nowThis phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…
Phase 2 • Sponsor: Mark Bernard • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New trial aims to outsmart drug resistance in colorectal cancer
Disease control Recruiting nowThis early-phase trial tests whether matching drug combinations to a patient's tumor characteristics can better control metastatic colorectal cancer. Researchers will use blood draws, biopsies, and imaging to track how tumors resist treatment. The study enrolls 100 adults with me…
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called ASP3082 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two parts: first, finding a safe dose of ASP3082 alone or with another drug; second, testing it with other cancer treatments. Up to …
Phase 1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can a weekly shot tame blood sugar in type 2 diabetes?
Disease control Recruiting nowThis phase 3 trial asks whether survodutide, an investigational weekly injection, can help adults with type 2 diabetes lower their blood sugar more than a placebo. Around 600 participants, who also follow diet and exercise or take standard diabetes medications (including insulin)…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug hopes to tackle MASH cirrhosis
Disease control Recruiting nowThis study tests a new medicine called BI 3802876 in adults with compensated cirrhosis caused by MASH (a type of fatty liver disease). The main goal is to see if the drug is safe and how the body handles it. Participants receive either the drug or a placebo as an infusion, and ar…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Smart insulin systems for kids: could early use change diabetes care?
Disease control Recruiting nowThis study looks at whether starting automated insulin delivery (AID) early in children aged 7–16 with type 1 diabetes improves blood sugar control, reduces stress for patients and families, and prevents long-term complications compared to standard insulin injections. One hundred…
Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
French study tests smart insulin Pump's Real-World impact on diabetes control
Disease control Recruiting nowThis study follows 350 people with type 1 diabetes in France who use the Control-IQ insulin pump system. Researchers want to see how safe and effective the system is over 12 months, focusing on blood sugar control and quality of life. Participants must be at least 6 years old and…
Sponsor: Tandem Diabetes Care, Inc. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug YL202 targets tough cancers in latest trial
Disease control Recruiting nowThis phase 2 trial tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will check how well it works and mon…
Phase 2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Triple attack on stomach cancer: can a Marker-Guided drug combo shrink tumors before surgery?
Disease control Recruiting nowResearchers in Japan are testing whether adding zolbetuximab to FLOT chemotherapy and durvalumab improves tumor response before surgery in adults with CLDN18.2-positive gastric or gastroesophageal junction cancer. The trial enrolls 29 participants with previously untreated, local…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Stomach cancer patients may soon get immunotherapy as a simple shot instead of an IV drip
Disease control Recruiting nowThis phase 3 trial compares a subcutaneous (under-the-skin) injection of tislelizumab to the standard intravenous (IV) infusion, both given with chemotherapy, as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has sp…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New pill targets genetic weakness in tough cancers
Disease control Recruiting nowThis early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New study tests switch from IV to At-Home shots for gut disease
Disease control Recruiting nowThis study is testing the drug vedolizumab (Entyvio) in 400 adults with moderate to severe ulcerative colitis or Crohn's disease. Participants first receive the drug through an IV for 6 weeks, then switch to injections under the skin for the rest of the year. The main goal is to …
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Could immunotherapy replace Chemo-Radiation after head and neck cancer surgery?
Disease control Recruiting nowThis phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) alone can work better than the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Sound waves vs. pancreatic cancer: a new way to attack deadly tumours
Disease control Recruiting nowResearchers are testing a non-invasive ultrasound technique called histotripsy in people with pancreatic cancer that cannot be removed by surgery. Histotripsy uses focused sound waves to create tiny bubbles inside the tumour that burst and break apart the cancer tissue without he…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New pill combo aims to shield hearts in diabetes patients
Disease control Recruiting nowThis large phase 3 trial is testing whether adding vicadrostat to the existing drug empagliflozin can reduce the risk of heart problems in adults with type 2 diabetes, high blood pressure, and heart disease. About 11,800 participants will take either the combination or a placebo …
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New weekly shot could reverse liver damage in MASH patients
Disease control Recruiting nowThis phase 3 trial tests survodutide, a weekly injection, in 1800 adults with MASH and moderate to advanced liver fibrosis. Participants receive either the drug or a placebo for up to 7 years, alongside diet and exercise advice. The goal is to see if survodutide can improve or re…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New Crohn's drug shows promise in major trial
Disease control Recruiting nowThis study tests a new medicine, JNJ-78934804, against an existing drug (guselkumab) in 460 people with moderate-to-severe Crohn's disease. The goal is to see if the new drug can reduce symptoms and heal the gut lining better at 48 weeks. Participants must have had Crohn's for at…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New cancer drug ABBV-400 enters early human testing
Disease control Recruiting nowThis early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New weekly shot aims to stop liver disease from getting worse
Disease control Recruiting nowThis Phase 3 trial tests whether survodutide, a weekly injection, can improve liver outcomes in 1590 adults with NASH or MASH cirrhosis. Participants are randomly assigned to receive survodutide or a placebo, along with diet and exercise counseling. The study will track serious l…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Community champions take on heart failure risk in Low-Income communities
Disease control Recruiting nowThis study tests whether a 6-month program of problem-solving training, community health worker support, and exercise coaching at a YMCA can improve fitness and heart health in 210 adults with type 2 diabetes, obesity, and low income. Participants are compared to those who receiv…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can a flexible dosing schedule improve esophageal cancer treatment?
Disease control Recruiting nowThis phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find …
Phase 2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug combo aims to tame tough Crohn's
Disease control Recruiting nowThis study tests if the drug vorinostat is safe and can help people with moderate-to-severe Crohn's disease by reducing gut inflammation. Participants who respond well may then receive a maintenance treatment with ustekinumab for up to two years. The goal is to control symptoms a…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New weekly shot could help obese diabetics shed pounds and control blood sugar
Disease control Recruiting nowThis Phase 3 trial is testing a new weekly injection called enicepatide for weight loss in 1600 people who are obese or overweight and also have type 2 diabetes. The drug works by mimicking natural hormones that help control appetite and blood sugar. Participants will receive eit…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New smart drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for bile duct cancer: targeted therapy duo takes on standard chemo
Disease control Recruiting nowThis study tests whether a new drug combination (trastuzumab deruxtecan plus rilvegostomig) works better than standard chemotherapy for people with advanced bile duct cancer that has a specific protein called HER2. About 620 adults with untreated, advanced HER2-positive bile duct…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug cocktail aims to stall pancreatic cancer after chemo
Disease control Recruiting nowThis phase II study tests whether a combination of two drugs, niraparib and ipilimumab, can slow tumor growth in people with metastatic pancreatic cancer whose disease has not worsened after platinum-based chemotherapy. About 68 participants will be randomly assigned to receive e…
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
MRNA vaccine takes on liver cancer in tiny early trial
Disease control Recruiting nowThis early study tests a PD-1 mRNA vaccine in 9 adults with advanced liver cancer that has not responded to standard treatments. The vaccine is given as weekly shots for four weeks, then a fifth shot a month later. The main goal is to check safety, but researchers will also see i…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Triple threat: immunotherapy and targeted drug join chemo to fight HER2+ gut cancers
Disease control Recruiting nowThis phase 2 study is testing whether adding two newer drugs—pembrolizumab (an immunotherapy) and trastuzumab (a targeted therapy)—to standard chemotherapy can help people with HER2-positive esophageal or stomach cancer that can be surgically removed. About 49 adults will receive…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Triple threat against pancreatic cancer: radiation, immunotherapy, and chemotherapy combined
Disease control Recruiting nowThis phase 2 trial tests a new treatment approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants receive targeted radiation therapy followed by a combination of two immunotherapy drugs (ipilimumab N01 and sintilimab) plus standa…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for liver cancer: Triple-Drug trial launches
Disease control Recruiting nowThis large Phase 3 trial is testing whether a new drug called rilvegostomig, combined with bevacizumab and with or without tremelimumab, can help people with advanced liver cancer live longer. About 1,220 participants who cannot have surgery or other local treatments will be rand…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug may reduce insulin shots for young diabetes patients
Disease control Recruiting nowThis study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if teplizumab can help control blood sugar and reduce the need for insulin at mealtimes. Participants will receive either teplizumab or a placebo …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat digestive tumors?
Disease control Recruiting nowThis study tests an experimental drug called BL-M08D1 in adults with advanced or metastatic digestive tract tumors and other solid tumors. The goal is to find the best dose and see how well it shrinks tumors and slows disease progression. Participants receive the drug by intraven…
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for advanced cancer patients as experimental drug enters human testing.
Disease control Recruiting nowThis early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can precision radiation and immunotherapy team up against abdominal colorectal cancer?
Disease control Recruiting nowResearchers are testing whether adding targeted radiation plus the immunotherapy drug cadonilimab to standard second-line chemotherapy helps adults with colorectal cancer that has spread only to the peritoneum. The trial enrolls about 198 participants and randomly assigns them to…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
First-in-Human trial tests BA1302 against advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of BA1302, an intravenous drug, in adults with advanced solid tumors including melanoma, breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The trial has two parts: a dose-escalation phase to find a saf…
Phase 1 • Sponsor: Shandong Boan Biotechnology Co., Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a Ready-Made mRNA vaccine train the immune system to fight many cancers?
Disease control Recruiting nowThis Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for pancreatic cancer: experimental drug combo enters large trial
Disease control Recruiting nowThis large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New Alpha-Particle therapy targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful type of radiation (alpha particles) directly to tumor cells that have a specific marker (SSTR2). The trial includes 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed b…
Phase 1/2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new targeted drug boost Chemotherapy's power against pancreatic cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy can help people with pancreatobiliary cancers, including pancreatic ductal adenocarcinoma. Participants will receive either the new combination or standar…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New clotting drug may cut bleeding risk in rare cancer surgery
Disease control Recruiting nowThis study tests whether a concentrated clotting drug (fibrinogen) can better control major blood loss during surgery for pseudomyxoma peritonei, a rare abdominal cancer. About 90 adults will be randomly assigned to receive either the drug or a standard blood product during their…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for tough colorectal cancer: LYL273 trial opens
Disease control Recruiting nowThis study tests a new drug, LYL273, in about 155 adults with metastatic colorectal cancer that has relapsed or stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. Participants must have limited liver involvement and no surg…
Phase 1/2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New combo therapy aims to outsmart 'Cold' rectal tumors
Disease control Recruiting nowThis Phase II trial tests whether adding a dual immunotherapy drug (iparomlimab/tuvonralimab) to standard chemoradiotherapy can improve outcomes for patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS), which usually does not respond to immu…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Device in the gut may help control diabetes
Disease control Recruiting nowThe STEP-1 trial tests a device called the RESET System in adults with type 2 diabetes and obesity whose blood sugar is not well controlled. The device is placed in the small intestine during an endoscopy and is designed to alter how the body absorbs nutrients. Participants are r…
Sponsor: Morphic Medical Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a Two-in-One immunotherapy shrink stomach tumors before surgery?
Disease control Recruiting nowResearchers are testing whether giving a dual-target immunotherapy drug alongside standard chemotherapy before surgery can shrink locally advanced gastric or gastroesophageal junction tumors. About 28 adults with previously untreated, HER2-negative disease will receive the combin…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Could a wait-and-see approach replace chemo for lung metastases in colorectal cancer?
Disease control Recruiting nowThis study looks at colorectal cancer patients whose disease is under control (no evidence of disease) but later develop a small number of lung tumors. Instead of starting chemotherapy right away, doctors will treat the lung spots with surgery or radiation and then watch closely.…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New shot aims to cure hepatitis b – early trial underway
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called AHB-137 in 84 adults with chronic hepatitis B who are already on antiviral therapy. The goal is to see if AHB-137 can clear the hepatitis B surface antigen and keep the virus under control, potentially leading to a functional c…
Phase 2 • Sponsor: AusperBio Therapeutics Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Engineered IL-2 drug tested against resistant cancers
Disease control Recruiting nowResearchers are testing an engineered interleukin-2 drug called MDNA11 in adults with advanced solid tumors. The trial gives MDNA11 alone or with pembrolizumab, an immune checkpoint inhibitor, to see which doses are safe and how the body processes the drug. It also looks for earl…
Phase 1/2 • Sponsor: Medicenna Therapeutics, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug MK-8294 tested in patients with advanced cancers
Disease control Recruiting nowThis early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Zapping a few growing liver tumors may let patients stay on their first treatment longer
Disease control Recruiting nowResearchers are testing whether adding radiotherapy to a few growing liver cancer spots while continuing first-line systemic therapy helps people live longer without their cancer getting worse, compared with switching to second-line drugs right away. The trial enrolls adults with…
Phase 3 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can sound waves supercharge immunotherapy against bile duct cancer?
Disease control Recruiting nowThis trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pfizer combo aims to outperform current therapy for stomach cancer
Disease control Recruiting nowThis study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…
Phase 2/3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New daily pill could help millions shed pounds
Disease control Recruiting nowThis phase 3 trial is testing a new daily pill called elecoglipron for weight loss in 4500 adults who are obese or overweight, with or without type 2 diabetes. Participants will take the pill or a placebo for 72 weeks, alongside diet and exercise. The main goal is to see how much…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a bone drug heal a diabetes foot complication?
Disease control Recruiting nowResearchers are testing whether denosumab, given as injections under the skin, can help heal acute Charcot foot in people with diabetes. The trial enrolls adults aged 18 to 80 with type 1 or type 2 diabetes and a newly diagnosed Charcot foot, which causes a red, swollen, warm foo…
Phase 3 • Sponsor: Ole Lander Svendsen • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug BL-M07D1 targets multiple HER2 cancers in early trial
Disease control Recruiting nowThis Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New monthly shot could help people with obesity shed pounds
Disease control Recruiting nowThis study tests a once-monthly injection called berobenatide to help adults with overweight or obesity lose weight. About 954 participants will receive either the drug or a placebo for 20 months. The goal is to see if the drug is safe and effective for weight loss, including in …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can adding heat to standard treatment help rectal cancer patients skip major surgery?
Disease control Recruiting nowThis phase III trial tests whether adding deep regional hyperthermia to standard radiochemotherapy improves outcomes for people with locally advanced rectal cancer. Participants receive chemoradiation with or without hyperthermia, followed by consolidation chemotherapy. Researche…
Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new injection outperform semaglutide for diabetes remission?
Disease control Recruiting nowThis trial is testing whether an experimental drug called BGM0504 can help people with early-stage type 2 diabetes and obesity achieve better blood sugar control and weight loss than a standard treatment, semaglutide. Participants will receive either BGM0504 or semaglutide as a o…
Phase 3 • Sponsor: BrightGene Bio-Medical Technology Co., Ltd. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for japanese youth: drug may delay type 1 diabetes onset
Disease control Recruiting nowThis study tests whether teplizumab, a drug already approved in the US, can safely delay the start of full-blown type 1 diabetes in Japanese people aged 8 to 34 who are at high risk (Stage 2). Participants will receive a 14-day IV treatment and be monitored for side effects and h…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Promising combo takes aim at Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis Phase 2 trial tests a chemotherapy regimen called NALIRIFOX combined with precise radiation (SBRT) in 42 people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this approach can delay cancer growth and improve survival. Partic…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug could delay type 1 diabetes progression
Disease control Recruiting nowThis study tests a new drug called SAB-142 in people recently diagnosed with type 1 diabetes. The goal is to see if it can help the body keep making its own insulin for longer, slowing the disease. About 159 people aged 5 to 40 will receive either the drug or a placebo, and resea…
Phase 2 • Sponsor: SAb Biotherapeutics, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Sound waves boost chemo attack on tough pancreatic tumors
Disease control Recruiting nowThis study tests whether adding Acoustic Cluster Therapy (ACT) to standard chemotherapy can shrink inoperable pancreatic tumors. About 25 adults with locally advanced pancreatic cancer will receive both treatments. The goal is to see if the combination improves response rates and…
Phase 2 • Sponsor: EXACT Therapeutics AS • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a single infusion prevent organ failure in severe pancreatitis?
Disease control Recruiting nowThis trial tests an experimental drug called SGC001 in people who are likely to develop severe acute pancreatitis, a painful inflammation of the pancreas that can lead to organ failure. Participants receive either SGC001 or a placebo as a single intravenous infusion alongside sta…
Phase 2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug aims to halt liver scarring in 2,150 patients with fatty liver disease
Disease control Recruiting nowThis phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…
Phase 3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for Crohn's? large trial tests tulisokibart
Disease control Recruiting nowThis phase 3 trial is testing a drug called tulisokibart in about 1,200 people with moderate-to-severe Crohn's disease who haven't had success with other treatments. The drug is given by IV or injection and aims to reduce symptoms and heal the gut lining. The study compares tulis…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New device aims to prevent leaks after colon cancer surgery
Disease control Recruiting nowThis study tests a device called ColoSeal ICD that is placed inside the colon after surgery to divert stool away from the surgical connection. The goal is to see if it is safe and feasible in 90 adults with rectal or rectosigmoid cancer. The device stays in place for about 10 day…
Sponsor: Averto Medical, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase 1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for ulcerative colitis: experimental drug JNJ-78934804 enters final testing phase
Disease control Recruiting nowThis phase 3 trial tests whether the experimental drug JNJ-78934804 can help people with moderate to severe ulcerative colitis achieve remission better than the existing drug guselkumab. About 644 participants will receive either the new drug or guselkumab, and researchers will c…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill shows promise for rare tumors in Mid-Stage trial
Disease control Recruiting nowThis phase 2 study tests belzutifan, a daily pill that blocks a protein called HIF-2α, in people with advanced rare cancers like pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, VHL disease-associated tumors, and certain other solid tumors. The goal is to see if …
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for advanced cancers? pfizer launches early trial of PF-08046033
Disease control Recruiting nowThis early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug targets KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…
Phase 1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill targets tough pancreatic cancer mutation
Disease control Recruiting nowThis study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Phase 4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: targeted drug shows promise
Disease control Recruiting nowThis phase 2 trial is testing the drug regorafenib as a second-line treatment for people with advanced colorectal cancer that has a specific mutation in the RAS gene. The study aims to see if a personalized, less intensive treatment approach can help control the cancer and improv…
Phase 2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Blood test could steer cancer treatment to right drug
Disease control Recruiting nowThis phase II trial tests whether a blood test that looks for genetic changes in circulating tumor cells can help doctors choose the right targeted therapy for colorectal cancer. 150 participants will either get treatment guided by the blood test or standard care. The goal is to …
Phase 2 • Sponsor: Matteo's Friends • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Less radiation, same control? new trial aims to boost quality of life for throat cancer patients
Disease control Recruiting nowThis study tests whether a shorter, lower-dose course of radiation after robotic surgery can improve quality of life for people with HPV-related throat cancer. About 42 adults who have had robotic surgery will receive a reduced radiation schedule. The goal is to see if this appro…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a dietitian program tame blood sugar in type 2 diabetes?
Disease control Recruiting nowResearchers at Kaiser Permanente are testing a six-session medical nutrition therapy program for adults with type 2 diabetes and high blood sugar. Registered dietitians deliver personalized diet and behavior-change support to about 600 patients in San Bernardino County. The trial…
Sponsor: Kaiser Permanente • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Kids with IBD get long-term safety check on vedolizumab
Disease control Recruiting nowThis study looks at the long-term safety of a drug called vedolizumab given as a shot under the skin to children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who did well on the drug in an earlier study will keep getting it, while those who didn…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a new antibody boost chemotherapy against advanced colorectal cancer?
Disease control Recruiting nowThis trial is testing whether adding an experimental antibody called petosemtamab to standard chemotherapy can help people with a certain type of advanced colorectal cancer that has returned or spread. Participants will receive either petosemtamab plus chemotherapy or a standard …
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Protein infusions eyed to quell liver inflammation in severe hepatitis
Disease control Recruiting nowResearchers are testing whether intravenous alpha-1 antitrypsin can reduce inflammation in people with severe alcohol-associated hepatitis. The trial enrolls 16 adults with severe disease who receive either the protein plus standard care or standard care alone. Participants get f…
Phase 2 • Sponsor: Medical University Innsbruck • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Sleeve or bypass? trial tests which surgery best tames type 2 diabetes
Disease control Recruiting nowResearchers compare two metabolic surgery techniques, sleeve and bypass, in adults with type 2 diabetes and moderate obesity. The goal is to see which operation leads to better blood sugar control and remission of diabetes. Thirty patients who have not reached their blood sugar t…
Sponsor: Médipôle Lyon-Villeurbanne • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New drug combo targets fatty liver in major trial
Disease control Recruiting nowThis study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…
Phase 2 • Sponsor: Eccogene • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a 5-Minute test and Same-Day pills cure more hepatitis c?
Disease control Recruiting nowResearchers in Armenia, Georgia, and Tanzania are comparing two ways to deliver hepatitis C care to people who inject drugs. One model confirms infection with an RNA test before starting sofosbuvir/velpatasvir, a daily pill that cures most hepatitis C. The other starts the same p…
Early phase 1 • Sponsor: Médecins du Monde • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Cancer drug adagrasib offers continued hope in rollover trial
Disease control Recruiting nowThis study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…
Phase 2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New study matches colorectal cancer patients to precision drugs
Disease control Recruiting nowThis study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment based on specific biomarkers found in their tumor. The goal is to see if these per…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New dissolvable device aims to lower hernia recurrence risk
Disease control Recruiting nowThis study tests a new device called ECLIPSIUM that uses a dissolvable material to hold mesh in place during hernia surgery. The goal is to see if it reduces the chance of the hernia coming back compared to current methods. About 240 adults with small to medium-sized hernias will…
Sponsor: Tissium • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New hope for hard-to-treat colon cancer? phase 3 trial launches
Disease control Recruiting nowThis study tests whether adding the experimental drug INCA33890 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer that is microsatellite stable (a type that doesn't respond well to immunotherapy). About 700 adults who have not had prior treat…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a Two-Pathway immunotherapy plus liver chemo make inoperable bile duct tumors removable?
Disease control Recruiting nowResearchers are testing whether a combination of retlirafusp alfa, famitinib, and liver-directed chemotherapy can shrink locally advanced intrahepatic cholangiocarcinoma enough to allow surgery. Adults with tumors that are technically removable but difficult to operate on directl…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New drug aims to stop colorectal cancer recurrence in patients with hidden tumor DNA
Disease control Recruiting nowThis phase 2 trial tests whether the investigational drug telisotuzumab adizutecan can prevent colorectal cancer from coming back in patients who have no visible tumors but still have cancer DNA in their blood after surgery. About 140 adults will be randomly assigned to receive e…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Old antibiotic, new hope? vancomycin trial for UC and PSC
Disease control Recruiting nowThis pilot study tests whether the antibiotic vancomycin can safely treat active ulcerative colitis in adults who also have primary sclerosing cholangitis, a liver condition. Fourteen participants will take vancomycin or a placebo for 4 weeks, with an optional 4-week extension. T…
Phase 2 • Sponsor: McMaster University • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Common antifungal drug shows promise against esophageal cancer
Disease control Recruiting nowThis phase II trial tests whether adding itraconazole, a common antifungal medication, to standard chemoradiation can improve outcomes for people with resectable esophageal cancer. About 78 participants will receive itraconazole before and after standard treatment, then undergo s…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New diabetes drug aims to help when current meds fall short
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called LY3457263 in 240 adults with type 2 diabetes who still have high blood sugar despite taking stable doses of semaglutide or tirzepatide. Participants receive weekly injections of either the new drug or a placebo for about 9 mont…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Smart labels and smartphones: can an app keep IBD patients on track?
Disease control Recruiting nowResearchers are studying whether a remote monitoring system can track how well people with inflammatory bowel disease stick to vedolizumab, a drug given either by IV infusion or under-the-skin injection. About 200 adults with Crohn's disease or ulcerative colitis who are starting…
Sponsor: Mercy Medical Center • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Engineered immune cells take on stomach cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment for stomach cancer that has spread to the lining of the abdomen. Ten adults will receive specially engineered immune cells (NK cells) infused directly into the abdomen, along with standard chemotherapy drugs. The main goals are to find…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Triple attack on pancreatic cancer: heat, chemo, and immunotherapy combined in new trial
Disease control Recruiting nowThis phase II trial tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. Participants first receive standard chemotherapy, then an endoscopic procedure that uses heat to destroy tumor tissue (EUS-RFA), followed by the immunotherapy dr…
Phase 2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Sound waves zap liver tumors in groundbreaking asian trial
Disease control Recruiting nowThis study tests histotripsy, a non-invasive treatment that uses focused ultrasound to destroy liver tumors without needles or surgery. It involves 40 adults with liver cancer who cannot have surgery or other standard treatments. The goal is to see if it is safe and effective at …
Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can surgery plus two drugs outsmart advanced liver cancer?
Disease control Recruiting nowResearchers are testing whether removing liver tumors surgically and then giving two drugs, camrelizumab and apatinib, helps people with advanced hepatocellular carcinoma that has spread to other organs. The trial enrolls adults with liver cancer that has spread to places like ly…
Phase 2/3 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New pill may help diabetics fast safely during ramadan
Disease control Recruiting nowThis study tests a once-daily pill called orforglipron in adults with type 2 diabetes who plan to fast during Ramadan. The goal is to see if the drug helps control blood sugar and weight without causing harm. About 130 participants will take the pill for up to 48 weeks, with clin…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New pill aims to tame Crohn's Flare-Ups
Disease control Recruiting nowThis study tests an experimental pill called MORF-057 (zotemtegrast) in 385 adults with moderate-to-severe Crohn's disease. The drug works by blocking a protein that drives gut inflammation. Participants will receive one of three doses of the drug or a placebo for 14 weeks to see…
Phase 2 • Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New immune drug AZD6750 targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can calming inflammation shield the heart?
Disease control Recruiting nowThis trial tests whether clazakizumab, an experimental anti-inflammatory drug, can lower a blood marker of inflammation called hsCRP in adults who have elevated levels and are at increased risk for heart problems. Participants must have conditions like established heart disease, …
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New Gene-Silencing drug aims to reverse liver scarring in MASH patients
Disease control Recruiting nowThis Phase 2 trial tests a drug called ALN-HSD, which uses gene silencing to target liver scarring in people with MASH, a fatty liver disease that can lead to cirrhosis. The study enrolls 120 adults with genetic risk factors and moderate-to-severe liver fibrosis. Researchers will…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted pill plus chemotherapy in Late-Stage trial
Disease control Recruiting nowThis Phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for liver cancer: pfizer tests experimental drug
Disease control Recruiting nowThis study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Robot with AI aims to make colorectal cancer surgery safer
Disease control Recruiting nowThis study tests whether an AI-enabled robotic stapler can reduce complications like leaks after colorectal cancer surgery compared to a standard stapler. About 200 adults undergoing planned robotic or laparoscopic surgery for non-metastatic colorectal cancer will be enrolled. Th…
Sponsor: Asian Institute of Gastroenterology, India • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New weekly shot could help chinese adults shed pounds and control diabetes
Disease control Recruiting nowThis phase 3 trial is testing a once-weekly injection called enicepatide in 300 Chinese adults who are obese or overweight, with or without type 2 diabetes. The drug works by mimicking two gut hormones to reduce appetite and improve blood sugar control. Participants will receive …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New drug combo aims to tame Crohn's Flare-Ups
Disease control Recruiting nowThis study tests whether adding a new drug (LY4395089) to an existing treatment (mirikizumab) works better than mirikizumab alone for adults with moderate-to-severe Crohn's disease. About 60 participants will be followed for 62 weeks to check safety and how well the combination r…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Could a breast cancer drug stop pancreatic cysts from becoming cancer?
Disease control Recruiting nowThis early-phase study tests whether tamoxifen, a drug commonly used for breast cancer, can shrink or stabilize pre-cancerous pancreatic cysts in women. The goal is to see if taking tamoxifen for up to 24 weeks can delay or eliminate the need for surgery. The study will enroll 15…
Phase 1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for colorectal cancer: experimental drug faces off against avastin
Disease control Recruiting nowThis Phase 3 trial is testing whether a new medicine called PF-08634404, combined with standard chemotherapy, works better than the current treatment Avastin plus chemo for people whose colorectal cancer has spread. About 800 participants who have not had prior treatment for meta…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Smarter radiation: could less be more for throat cancer patients?
Disease control Recruiting nowThis study tests whether giving less radiation to healthy lymph nodes can reduce side effects for people with oropharynx cancer. The approach uses a computer model to personalize which lymph nodes need treatment. The trial will enroll 120 patients and track if cancer returns in u…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for Tough-to-Treat colon cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis Phase 3 trial tests a new drug called precemtabart tocentecan, alone or with bevacizumab, against a standard treatment for metastatic colorectal cancer that has progressed after prior therapies. About 1,020 participants will be randomly assigned to one of three treatment gro…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug, brelovitug, to an existing treatment (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the infection will receive either drug to see which better controls the virus and normalizes liver enzymes. The…
Phase 3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New drug combo aims to protect kidneys in diabetes
Disease control Recruiting nowThis Phase 2 trial tests two experimental drugs, ALN-ANG3 and evinacumab, in 270 people with diabetic kidney disease. The drugs block a protein called ANGPTL3 to lower blood fats. Researchers will measure changes in urine protein and kidney function over time to see if the drugs …
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New pill could tame ulcerative colitis Flare-Ups
Disease control Recruiting nowThis study tests an oral drug called LY4268989 (MORF-057) in adults with moderate-to-severe ulcerative colitis. About 1,431 participants will receive either the drug or a placebo for up to 108 weeks. The goal is to see if the drug can safely help control the disease and improve s…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Five-Year watch: can a daily liver drug keep rare disease at bay?
Disease control Recruiting nowResearchers are following people with Alagille syndrome or progressive familial intrahepatic cholestasis who take Livmarli (maralixibat) for up to five years. The study tracks liver transplants, biliary surgery, deaths, growth, bleeding, and fractures to see how the drug performs…
Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New biologic TRK-950 joins forces with standard chemo to fight stomach cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental biologic called TRK-950 to the standard combination of ramucirumab and paclitaxel helps people with advanced stomach or gastroesophageal junction cancer. Participants receive either the standard two-drug regimen or the stand…
Phase 2 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New weekly shot could help people with obesity and diabetes shed pounds
Disease control Recruiting nowThis study tests a new once-weekly medicine called eloralintide to help people with obesity or overweight and type 2 diabetes lose weight. About 1035 adults will receive either the drug or a placebo for around 75 weeks. Researchers will measure changes in body weight, fat, waist …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Spanish-language pump training aims to close diabetes tech gap for latino youth
Disease control Recruiting nowThis trial tests whether a culturally tailored, Spanish-language onboarding and support program helps Latino youth aged 10–20 with type 1 diabetes adopt and consistently use the Medtronic MiniMed 780G automated insulin delivery system. Participants receive one-on-one nutrition su…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for tough pancreatic cancers: drug combo aims to shrink tumors before surgery
Disease control Recruiting nowThis early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…
Phase 1 • Sponsor: PanTher Therapeutics • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Light therapy takes aim at tough pancreatic tumors
Disease control Recruiting nowThis early-stage trial tests a new treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The therapy uses a light-sensitive drug and a special light delivered through a thin tube into the blood vessels feeding the tumor. The goal is to see if it …
Phase 1 • Sponsor: Impact Biotech Ltd • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Could a pill save insulin cells? new trial for kids and young adults with type 1 diabetes
Disease control Recruiting nowThis study tests whether baricitinib, a pill, can help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. About 300 children and young adults (ages 1 to under 36) will take either baricitinib or a placebo for 60 weeks. The goal is to see i…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can these diabetes drugs stop liver failure? major trial launches
Disease control Recruiting nowThis large phase 3 study is testing whether two drugs, tirzepatide and retatrutide, can prevent major liver complications in 4,500 adults with high-risk metabolic fatty liver disease (MASLD). Participants are randomly assigned to receive one of the drugs or a placebo for about 4 …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for gut disease: experimental drugs enter human trials
Disease control Recruiting nowThis phase 2 study is testing two new drugs — mirikizumab (given by IV or injection) and LY4395089 (a pill) — in 60 adults with moderately to severely active ulcerative colitis or Crohn's disease. The goal is to see if these treatments are safe and can help control the disease. T…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can a Dual-Antibody combo clear rectal tumors before surgery?
Disease control Recruiting nowResearchers are testing whether adding QL1706, a dual PD-1/CTLA-4 antibody, to chemoradiotherapy before surgery can effectively treat MSS-type low rectal cancer. The trial enrolls 60 people aged 18 to 75 with tumors in the lower rectum. Participants receive short or long radiothe…
Phase 2/3 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New combo pill aims to tame stubborn ulcerative colitis
Disease control Recruiting nowThis study tests whether adding a new oral drug, LY4268989, to the existing treatment mirikizumab works better than mirikizumab alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive either the combination or mirikizumab plus a placebo fo…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
One endoscopy session could rewrite fatty liver treatment plans
Diagnosis Recruiting nowResearchers are studying whether a detailed liver assessment done during one endoscopy session changes treatment decisions for adults at high risk of metabolic dysfunction-associated steatotic liver disease. The study enrolls 500 adults with suspected MASLD and at least one risk …
Sponsor: University Hospital Muenster • Aim: Diagnosis
Last updated Oct 17, 2026 08:00 UTC
-
Could a string swallowed in a pill replace endoscopy for EoE?
Diagnosis Recruiting nowThis study tests whether a simple esophageal string test (EST) can diagnose eosinophilic esophagitis (EoE) in people who have trouble swallowing. Participants swallow a capsule with a nylon string that collects fluid from the esophagus, which is then analyzed. The results will be…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Diagnosis
Last updated Oct 17, 2026 08:00 UTC
-
Blood markers eyed as early warning for severe pancreatitis
Diagnosis Recruiting nowResearchers at Ohio State University are studying whether certain immune proteins and cells in the blood can predict which cases of acute pancreatitis will become severe. Adults aged 18 to 75 who arrive at the hospital with acute pancreatitis provide blood samples and answer surv…
Sponsor: Ohio State University • Aim: Diagnosis
Last updated Oct 17, 2026 08:00 UTC
-
Blood test may boost colon cancer screening in those who skip it
Diagnosis Recruiting nowThis study looks at whether offering a blood test (Guardant Shield) can increase colon cancer screening in people who are overdue. About 500 adults aged 45-85 will either get a standard reminder to screen or also have the option to give a blood sample. The goal is to see if the b…
Sponsor: University of Miami • Aim: Diagnosis
Last updated Oct 17, 2026 08:00 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden cancer cells
Diagnosis Recruiting nowThis early-stage trial tests a fluorescent dye attached to the cancer drug nivolumab. The dye is meant to make cancer cells glow during surgery, helping surgeons remove them more precisely. The study will enroll 40 people with head and neck cancer who are already scheduled for su…
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Oct 17, 2026 08:00 UTC
-
Can a new PET tracer light up hidden cancers?
Diagnosis Recruiting nowThis trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…
Sponsor: Peking University Third Hospital • Aim: Diagnosis
Last updated Oct 17, 2026 00:00 UTC
-
Could a blood test spot pancreatic cancer before it hides behind other pancreatic diseases?
Diagnosis Recruiting nowPancreatic cancer is hard to catch early because its symptoms overlap with chronic pancreatitis and benign pancreatic cysts. This study asks whether a panel of blood proteins, including GDF-15, ICAM-1, osteopontin, CXCL10, HGF, Nectin-4, periostin, and VEGF-A, can distinguish pan…
Sponsor: Grigore T. Popa University of Medicine and Pharmacy • Aim: Diagnosis
Last updated Oct 17, 2026 00:00 UTC
-
New scan could spot liver danger before It's too late
Diagnosis Recruiting nowThis study aims to improve how doctors see liver damage (cirrhosis), liver cancer, and high blood pressure in the liver using a special PET/MRI scan. About 45 adults with cirrhosis will get this scan to see if it gives clearer pictures than current methods. The goal is to make di…
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Oct 16, 2026 00:00 UTC
-
Could a 15-Minute ultrasound replace the scope for IBD monitoring?
Diagnosis Recruiting nowThis trial asks whether adding a quick, painless intestinal ultrasound to standard check-ups can change how doctors treat inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Adults with IBD who are already scheduled for a colonoscopy are randomly a…
Sponsor: Mahidol University • Aim: Diagnosis
Last updated Oct 16, 2026 00:00 UTC
-
AI vs. standard scope: which spots hidden polyp regrowth best?
Diagnosis Recruiting nowAfter large colorectal polyps are removed in pieces, tissue can grow back at the scar. Doctors need a reliable way to spot this regrowth during follow-up colonoscopies. This trial compares four imaging methods: standard white light, texture and color enhancement (TXI), narrow-ban…
Sponsor: University Hospital Virgen de las Nieves • Aim: Diagnosis
Last updated Oct 16, 2026 00:00 UTC
-
Laser microscope aims to spot dangerous pancreatic cysts
Diagnosis Recruiting nowResearchers are testing a technique called confocal laser endomicroscopy to help diagnose pancreatic cysts. The study enrolls adults with cysts at least 2 cm wide who are referred for an endoscopic ultrasound. During the procedure, doctors use a laser and a fluorescent dye to vie…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Can anal screening catch cancer early in women with HPV history?
Diagnosis Recruiting nowWomen who have had HPV-related cervical, vulvar, or vaginal disease face a higher risk of anal cancer precursors. This trial tests three screening approaches in 300 HIV-negative women aged 35 and older: anal cytology, HPV testing on a sample each woman collects herself, and HPV t…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
New MRI scan could spare liver patients from painful needle procedure
Diagnosis Recruiting nowThis study tests whether a special 4D-flow MRI can accurately measure blood flow and pressure in the liver without needing an invasive catheter. Researchers will enroll 60 adults with cirrhosis and compare MRI results to the standard pressure test. If it works, this could make di…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Can a new tracer make tumors light up on scans?
Diagnosis Recruiting nowThis trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Blood test aims to detect tumor DNA without biopsy
Diagnosis Recruiting nowResearchers at the Grand Hôpital de Charleroi are validating a molecular test called TST79 that looks for circulating tumor DNA in blood plasma. The study enrolls 15 patients with various cancers, including lung, colorectal, breast, prostate, melanoma, and others, who are undergo…
Sponsor: Grand Hôpital de Charleroi • Aim: Diagnosis
Last updated Oct 11, 2026 00:00 UTC
-
Can a simple score predict hidden heart disease in fatty liver patients?
Diagnosis Recruiting nowResearchers are studying whether standard heart risk calculators match the results of coronary artery calcium scans in Thai patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The trial enrolls 251 adults who have fatty liver disease but no symptoms of…
Sponsor: Watcharasak Chotiyaputta • Aim: Diagnosis
Last updated Oct 10, 2026 00:00 UTC
-
Microwave gadget could spot hidden polyps during colonoscopy
Diagnosis Recruiting nowThis study tests a new microwave-based device, called MiWEndo, that is used during a standard colonoscopy to help doctors find polyps in the colon. About 50 people who already have a polyp in their rectum will take part. The goal is to see if the device is safe and can find more …
Sponsor: MiWEndo Solutions S.L. • Aim: Diagnosis
Last updated Oct 10, 2026 00:00 UTC
-
Simple blood test could spot cancer earlier in High-Risk individuals
Diagnosis Recruiting nowThis study is testing a new blood test that looks for DNA fragments from tumors in people with hereditary cancer syndromes like Lynch syndrome or BRCA mutations. The goal is to see if the test can find cancers earlier than standard screening methods. Researchers will compare canc…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Oct 10, 2026 00:00 UTC
-
AI-Powered ECGs could spot silent heart disease before It's too late
Diagnosis Recruiting nowThis study tests whether artificial intelligence (AI) can analyze routine heart tests (ECGs) to find hidden heart problems like weak heart muscle, valve issues, or high lung pressure. About 590 adults without a prior heart disease diagnosis will have ECGs taken with standard mach…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Oct 10, 2026 00:00 UTC
-
Can a Partner's support help prevent type 2 diabetes?
Prevention Recruiting nowResearchers are testing whether a lifestyle program that includes a romantic partner works better than the standard diabetes prevention program for adults at high risk of type 2 diabetes. The trial enrolls 324 adults with prediabetes or other risk factors, along with their partne…
Sponsor: University of Utah • Aim: Prevention
Last updated Oct 17, 2026 08:00 UTC
-
Walk and eat smart: new study aims to ward off dementia and diabetes
Prevention Recruiting nowThis study tests two lifestyle programs in 400 older African American and non-Hispanic white adults at risk for dementia and diabetes. One group does aerobic exercise three times a week; the other learns to follow the MIND diet, which emphasizes berries, greens, and whole grains.…
Sponsor: University of California, Davis • Aim: Prevention
Last updated Oct 17, 2026 08:00 UTC
-
Can a sugar pill prevent Crohn's from coming back?
Prevention Recruiting nowResearchers test whether an oral glycan supplement can prevent Crohn's disease from returning after surgery. The trial enrolls 30 adults who had surgery to remove diseased bowel. Participants take the supplement to see if it changes gut bacteria and immune response, which might s…
Sponsor: GLSMED Learning Health S.A. • Aim: Prevention
Last updated Oct 17, 2026 00:00 UTC
-
Could a Cancer-Killing pill stop colon cancer before it starts?
Prevention Recruiting nowThis early-phase study tests the safety of a drug called ONC201 (dordaviprone) in 36 adults at high risk for colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal ones. Researcher…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Oct 17, 2026 00:00 UTC
-
Can a Pharmacist's checklist stop dangerous low blood sugar?
Prevention Recruiting nowSevere low blood sugar is a serious risk for people with diabetes, causing falls, heart problems, and hospital stays. Researchers at Kaiser Permanente developed a simple guide called 'Hypoglycemia on a Page' to help prevent it. In this study, they compare two groups of high-risk …
Sponsor: Kaiser Permanente • Aim: Prevention
Last updated Oct 16, 2026 00:00 UTC
-
Can chlorine in maternity wards stop deadly newborn infections?
Prevention Recruiting nowThis trial tests whether adding chlorine to water supplies and disinfecting surfaces in rural Kenyan maternity wards reduces infections in newborns and their mothers. Facilities receive automated water chlorinators, chlorine solution, and cleaning supplies, along with infection p…
Sponsor: University of California, Berkeley • Aim: Prevention
Last updated Oct 15, 2026 00:00 UTC
-
Mobile clinic brings heart risk checks to indigenous communities
Prevention Recruiting nowResearchers at Laval University are studying a mobile healthcare unit that travels to Indigenous and remote communities in Canada to offer cardiovascular risk screening. About 500 adults with a body mass index above 27 can take part. The team measures blood pressure, cholesterol,…
Sponsor: Laval University • Aim: Prevention
Last updated Oct 11, 2026 00:00 UTC
-
Could an antibiotic rinse during appendectomy stop deadly abscesses?
Prevention Recruiting nowComplicated appendicitis often leads to a painful pocket of pus called an intra-abdominal abscess after surgery. Researchers are testing whether washing the belly with a gentamicin and clindamycin solution during laparoscopic appendectomy can prevent these abscesses. The trial en…
Phase 3 • Sponsor: Spaarne Gasthuis • Aim: Prevention
Last updated Oct 11, 2026 00:00 UTC
-
Can a surgical drain stop bile leaks after Children's liver surgery?
Prevention Recruiting nowBile leakage is a serious complication after liver resection in children and can require more procedures or repeat surgery. This trial enrolls 12 children and adolescents up to age 18 who are having liver resection and are at high risk of bile leakage because their tumors sit nea…
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Prevention
Last updated Oct 11, 2026 00:00 UTC
-
A daily pill aims to stop overweight from turning into obesity and diabetes
Prevention Recruiting nowThis phase 3 trial tests whether orforglipron, a daily oral medication, can help overweight adults reduce their risk of developing obesity-related complications such as type 2 diabetes, high blood pressure, and high cholesterol, as well as progression to class 1 obesity. Particip…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Could a pill delay diabetes in kids? new trial hopes so
Prevention Recruiting nowThis study tests whether the drug baricitinib can delay the onset of type 1 diabetes in children aged 1 to 36 months who are at high risk. Participants take baricitinib or a placebo daily for up to 5 years. The goal is to see if the drug can push back or prevent the need for insu…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Fish oil showdown: which type fights diabetes best?
Prevention Recruiting nowThis study tests whether two types of fish oil, EPA and DHA, can improve metabolic health in people at high risk for type 2 diabetes. Over 12 weeks, 84 participants will take daily capsules of EPA, DHA, or a placebo (corn oil) and undergo specialized tests to measure insulin func…
Phase 2 • Sponsor: May Faraj, PDt, PhD • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Finger-Prick test could guide hepatitis b treatment in pregnancy
Prevention Recruiting nowPregnant women with hepatitis B can pass the virus to their babies during birth. To prevent this, guidelines recommend treating women with high levels of the virus using the drug tenofovir. However, many clinics in low-income countries cannot measure virus levels. This trial comp…
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
Seaweed extract tested as chemo fatigue fighter
Symptom relief Recruiting nowThis study tests whether fucoidan, a supplement from brown seaweed, can prevent or reduce fatigue in people with gastrointestinal or gynecologic cancers who are starting chemotherapy. About 34 participants will receive either fucoidan or a placebo daily for up to 16 weeks. Resear…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
New study aims to ease pain after gallbladder removal
Symptom relief Recruiting nowThis study compares two common pain relief techniques after laparoscopic gallbladder removal: local anesthetic injected into the surgical cuts versus an ultrasound-guided nerve block near the belly button. The goal is to see which method better reduces pain and the need for opioi…
Sponsor: Sisli Hamidiye Etfal Training and Research Hospital • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Can a vitamin cocktail soothe diabetic nerve pain and speed wound healing?
Symptom relief Recruiting nowResearchers are testing whether a supplement combining alpha-lipoic acid, vitamins B1, B6, B12, and vitamin E improves nerve symptoms more than a vitamin B-complex alone in people with type 2 diabetes and diabetic symmetrical polyneuropathy. About 100 participants at one hospital…
Sponsor: BREGO Life Sciences • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Electric acupoint therapy may speed digestion and ease pain after stomach cancer surgery
Symptom relief Recruiting nowThis study tests whether transcutaneous electrical acupoint stimulation (TEAS) — a needle-free treatment that sends mild electrical pulses through sticky pads on the skin — can help people recover faster after laparoscopic surgery for stomach cancer. Researchers are comparing thr…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Nerve zapper may offer relief for MS-related bladder, bowel, and sexual issues — trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether a device called sacral neuromodulation (InterStim X) can improve bladder, bowel, and sexual function in people with multiple sclerosis who have not responded to standard treatments. Participants who show at least 50% improvement during a test period will …
Sponsor: Odense University Hospital • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Could a simple drug combo speed up recovery after colon cancer surgery?
Symptom relief Recruiting nowThis study tests whether giving lidocaine through a vein during surgery, plus injecting ropivacaine into the surgical cuts, helps people recover better after laparoscopic colon cancer surgery. About 182 adults will be randomly assigned to get either the lidocaine plus ropivacaine…
Phase 3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Symptom relief
Last updated Oct 17, 2026 08:00 UTC
-
Bidets put to the test for Post-Surgery wound care
Symptom relief Recruiting nowResearchers compare an electronic bidet with standard water rinsing for cleaning wounds after surgery for anal fistula or hemorrhoids. Forty adults who have had these operations will use one of the two methods. The study measures comfort, ease of use, and how clean patients feel,…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
A pill to stop cancer treatment from stealing appetite?
Symptom relief Recruiting nowThis phase 3 trial tests whether megestrol acetate, a drug that stimulates appetite, can prevent weight loss in people with nasopharyngeal carcinoma undergoing chemoradiotherapy. Half of the 204 participants will take the drug daily for 11 weeks, and the other half will take a pl…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
How deep should surgeons cut? trial tests two POEM techniques for achalasia
Symptom relief Recruiting nowAchalasia makes it hard to swallow because the muscles at the bottom of the esophagus fail to relax. POEM is a minimally invasive procedure that cuts those muscles through the mouth, but doctors do not know how deep the cuts should go. This trial randomly assigns 70 adults with t…
Phase 2 • Sponsor: Cairo University • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
New study tests virtual coaching to tackle diabetes and mental health together
Symptom relief Recruiting nowThis study tests a virtual health coaching program for adults with type 2 diabetes who also face mental health challenges like anxiety or diabetes distress. Participants receive weekly coaching calls, support from a care team, and online tools to help manage both conditions. The …
Sponsor: McMaster University • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
New artificial liver system tested against deadly liver failure
Symptom relief Recruiting nowResearchers are testing a new artificial liver support system called CABA, which combines two adsorption columns with plasma exchange, in people with end-stage liver disease and inflammation. The trial enrolls about 40 adults aged 18 to 70 with severe liver failure. The main goal…
Phase 4 • Sponsor: Qin Ning • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
Hope for mitochondrial disease: new drug targets debilitating fatigue
Symptom relief Recruiting nowThis study tests whether the drug sonlicromanol can reduce fatigue and improve physical abilities like balance and leg strength in adults with a specific genetic form of mitochondrial disease. About 220 participants will take either the drug or a placebo twice daily for 52 weeks.…
Phase 3 • Sponsor: Khondrion BV • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
Can a Psychologist's program ease the toll of major gut surgery?
Symptom relief Recruiting nowResearchers at Northwestern University are testing a psychological program called PREPARE-GI for adults who have lasting stress from past medical experiences and are scheduled for complex gastrointestinal surgery. The program involves eight one-hour sessions with a licensed psych…
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
New drug aims to fight deadly wasting in pancreatic cancer patients
Symptom relief Recruiting nowThis study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…
Phase 2/3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
Can Cuff-Restricted light weights rebuild strength after colorectal cancer?
Symptom relief Recruiting nowResearchers are testing whether low-load resistance training combined with blood flow restriction can improve muscle strength, physical function, and cancer-related fatigue in colorectal cancer survivors with probable sarcopenia. Participants do supervised resistance exercises tw…
Sponsor: Ahmed Adel Ahmed Elsayed Ali Radwan • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
Cannabis tested to ease Cancer's heavy symptom burden
Symptom relief Recruiting nowPeople with advanced pancreatic or colorectal cancer often face a mix of hard-to-treat symptoms that hurt their quality of life. This phase II trial tests whether medical cannabis can reduce that symptom burden. Half the participants receive medical cannabis for eight weeks right…
Phase 2 • Sponsor: HealthPartners Institute • Aim: Symptom relief
Last updated Oct 16, 2026 00:00 UTC
-
New lozenge aims to ease radiation mouth sores for hours
Symptom relief Recruiting nowThis phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …
Phase 3 • Sponsor: OncoZenge AB • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Knee pain relief without blood sugar spikes? new study tests two steroid options for diabetics
Symptom relief Recruiting nowThis study compares two steroid injections for knee osteoarthritis in people with type 2 diabetes. It aims to see which one controls pain better while causing fewer blood sugar spikes. About 120 adults with diabetes and knee arthritis will receive either a long-acting or short-ac…
Phase 4 • Sponsor: University of Kansas Medical Center • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
App and talk therapy aim to ease diabetes distress in kids
Symptom relief Recruiting nowThis study tests whether a program that combines a smartphone app with face-to-face therapy sessions can improve psychological well-being in children and adolescents with type 1 diabetes. The goal is to reduce diabetes-related distress and help young patients better manage their …
Sponsor: Maimónides Biomedical Research Institute of Córdoba • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
New MRI technique aims to spare saliva glands during cancer radiation
Symptom relief Recruiting nowThis Phase 2 trial tests whether using MRI to map saliva ducts before radiation therapy can reduce dry mouth in people with oropharyngeal cancer. About 98 participants will be randomly assigned to standard radiation planning or a new approach that spares the parotid ducts. The ma…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Smaller incision, same relief? new trial tests less invasive POEM for achalasia
Symptom relief Recruiting nowThis study compares a shorter muscle cut (4-5 cm) during a procedure called POEM to the standard longer cut (8-10 cm) for people with certain swallowing disorders. The goal is to see if the shorter cut works just as well at relieving symptoms like trouble swallowing and chest pai…
Phase 3 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
New adaptive palliative care model aims to give right care at the right time
Symptom relief Recruiting nowThis study tests a home-based palliative care program called TIER-PC that adjusts the care team based on a patient's symptoms and ability to function. It includes 60 adults with advanced heart failure or certain cancers living in Manhattan. The program adds more specialists—like …
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Can a personalized diet heal the gut in Crohn's disease?
Symptom relief Recruiting nowResearchers test whether a mostly vegetarian Mediterranean diet plus lifestyle changes, followed by avoiding a specific food that endoscopy shows harms the gut barrier, can improve gut barrier integrity and ease symptoms in Crohn's disease. Thirty adults with Crohn's and food-rel…
Sponsor: Universität Duisburg-Essen • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Which probiotic stops Kids' diarrhea faster? new trial aims to find out
Symptom relief Recruiting nowThis study will compare two probiotic drinks—Bacillus clausii and a mix of four bacterial strains—in 138 children aged 1 to 5 with acute watery diarrhea. All children will also receive standard care like rehydration and zinc. The goal is to see which probiotic reduces diarrhea du…
Sponsor: Children Hospital and Institute of Child Health, Lahore • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Nano drug aims to boost appetite and weight in pancreatic cancer patients
Symptom relief Recruiting nowThis study tests a new nano-formulation of megestrol acetate, a drug used to stimulate appetite and promote weight gain, in patients with advanced pancreatic cancer who suffer from anorexia-cachexia syndrome. The trial will enroll 56 patients and compare those receiving the nano-…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Gut feeling: can a probiotic lift mood in stomach disorder?
Symptom relief Recruiting nowThis study tests whether a probiotic called Clostridium butyricum can help reduce anxiety and depression in people with functional dyspepsia (a common stomach disorder). 180 adults will receive either the probiotic or a placebo for 4 weeks, alongside standard stomach medication. …
Phase 4 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Cancer injection satisfaction study recruits 700 patients
Symptom relief Recruiting nowThis study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …
Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Can coaching sessions help rectal cancer patients navigate treatment?
Symptom relief Recruiting nowResearchers at Massachusetts General Hospital are testing a program called PATHWAYS for people with locally advanced rectal cancer who are about to start chemotherapy and radiation before surgery. The program combines four behavioral coaching sessions with a patient education gui…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Which bowel care tool wins the race? trial pits suppository, enema, and irrigation device
Symptom relief Recruiting nowPeople with spinal cord injuries often rely on a bowel program to manage neurogenic bowel, a condition that makes it hard to control bowel movements. This trial compares three tools used during those programs: a bisacodyl suppository, a mini enema called Enemeez, and a transanal …
Sponsor: Casa Colina Hospital and Centers for Healthcare • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Can insoles and nerve stimulation save diabetic feet from amputation?
Symptom relief Recruiting nowDiabetic foot ulcers are a common and serious complication of diabetes that can lead to amputation. Researchers at the University of Lahore are testing whether adding custom polyethene foam insoles with a Poron top layer, and transcutaneous electrical nerve stimulation (TENS), to…
Sponsor: University of Lahore • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Acupressure shows promise for diabetes and anxiety in elderly
Symptom relief Recruiting nowThis study tests whether acupressure, a technique that applies gentle pressure to specific points on the body, can lower blood sugar and reduce anxiety in people aged 65 and older with diabetes. Forty-eight participants will receive either real acupressure or a sham version for 6…
Sponsor: Abant Izzet Baysal University • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Bright light, bright gut: could morning therapy ease IBD?
Symptom relief Recruiting nowThis study tests whether one hour of morning light therapy each day for four weeks can improve sleep quality and reduce inflammation in adults with ulcerative colitis who have active inflammation and poor sleep. Thirty participants will wear a sleep tracker, complete surveys, and…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Can a talking program ease the emotional weight of a liver cancer diagnosis?
Symptom relief Recruiting nowResearchers at Massachusetts General Hospital are testing HARMONY, a psychoeducational program for people recently diagnosed with hepatocellular carcinoma, the most common form of liver cancer. The study enrolls about 50 adults who received their diagnosis within the past six mon…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Can two gut bacteria strains calm Kids' stomach pain?
Symptom relief Recruiting nowResearchers test whether a daily probiotic mixture of Lactobacillus rhamnosus GG and Lactobacillus plantarum 299V reduces abdominal pain and improves bowel habits in children aged 4 to 18 with irritable bowel syndrome. The trial enrolls 124 children who have daily abdominal pain …
Sponsor: University of Bari • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
New shot could ease IBS-D symptoms in major trial
Symptom relief Recruiting nowThis Phase 2 study tests whether brenipatide, given as an injection under the skin, can safely reduce abdominal pain and improve stool consistency in adults with diarrhea-predominant irritable bowel syndrome (IBS-D). About 531 participants will receive either the drug or a placeb…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
Puzzle power: activity book aims to boost insulin skills in diabetic kids
Symptom relief Recruiting nowThis study tests whether an activity book called 'Think-Find-Solve' can improve insulin self-management in children aged 8-12 with type 1 diabetes. Forty children and their parents will take part, with one group using the book for three months. The goal is to see if the book help…
Sponsor: Marmara University • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
New shot for stubborn constipation pain enters Mid-Stage trial
Symptom relief Recruiting nowThis study tests an injected drug called brenipatide in 342 adults with irritable bowel syndrome with constipation (IBS-C). Participants will receive either the drug or a placebo for about 35 weeks. The goal is to see if brenipatide safely reduces abdominal pain and improves bowe…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
Gene therapy patients monitored for 15 years in safety Follow-Up
Knowledge-focused Recruiting nowThis study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
New ulcerative colitis drug put through drug interaction test
Knowledge-focused Recruiting nowThis early-phase study is testing whether afimkibart, an experimental drug for ulcerative colitis, changes how the body processes common medications like caffeine, warfarin, and omeprazole. About 25 people with moderate to severe active ulcerative colitis will receive afimkibart …
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
VHL pancreatic tumors under the microscope: new scan tested
Knowledge-focused Recruiting nowThis study follows people with von Hippel-Lindau (VHL) disease who have pancreatic tumors or cysts. The goal is to learn how these growths change over time and to see if a special type of scan (68-Gallium DOTATATE PET/CT) can find them better. Participants will have regular check…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
18-Year study to uncover roots of childhood obesity and diabetes
Knowledge-focused Recruiting nowThis study follows 1,500 pregnant women and their children for up to 18 years to understand how a mother's health, lifestyle, and environment affect her child's growth and risk for obesity, diabetes, and fatty liver. Mothers attend visits during pregnancy and after birth, while c…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists watch immune system in action to unlock IBD mysteries
Knowledge-focused Recruiting nowThis study aims to learn how the immune system controls inflammation in the gut for people with Crohn's disease or ulcerative colitis. Up to 1,000 participants aged 0 to 75 will receive standard medical care and may provide blood, tissue, or white blood cell samples. No experimen…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Gene study aims to unlock cancer risks in families
Knowledge-focused Recruiting nowThis study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…
Sponsor: Mohamed Abdel-Rahman • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
New study tracks colon polyp patients to improve cancer care
Knowledge-focused Recruiting nowThis study follows 500 people who had a malignant colorectal polyp removed. Researchers want to learn how often the cancer stays, comes back, or spreads. They will also study how patients and doctors decide on next steps after removal. Participants share medical records and get f…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists launch deep dive into rare liver disease PSC
Knowledge-focused Recruiting nowThis study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatmen…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists seek clues to fungal infections in immune system study
Knowledge-focused Recruiting nowThis study aims to understand why some people are more prone to fungal infections, especially from Candida yeast. Researchers will collect blood, saliva, urine, and tissue samples from people with immune disorders, their family members, and healthy volunteers. No treatment is giv…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
New study investigates why heart disease hits african americans differently
Knowledge-focused Recruiting nowThis study looks at how obesity and body fat affect heart disease risk in 2,000 healthy African American men and women. Researchers will measure body fat, blood fats, and insulin function to see if risk factors differ by sex. The goal is to understand why heart disease rates are …
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists launch deep dive into IBD to uncover hidden clues
Knowledge-focused Recruiting nowThis study will follow 100 adults with Crohn's disease, ulcerative colitis, or other IBD, plus their healthy relatives, for up to 3 years. Researchers will collect blood, stool, tissue samples, and imaging to track how immune cells and genetics change over time. The goal is to fi…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Texting homeless adults to boost colon cancer screening
Knowledge-focused Recruiting nowThis study tests whether sending text messages can encourage homeless adults aged 45-75 to complete colorectal cancer screening. About 588 participants from shelter clinics in New York City will be randomly assigned to receive SMS reminders or standard care. The goal is to see if…
Sponsor: George Washington University • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Could a tiny sensor replace the glucose drink test for new moms?
Knowledge-focused Recruiting nowThis study looks at whether a continuous glucose monitor (CGM) — a small sensor worn under the skin — is an acceptable and useful tool for checking diabetes risk in women who recently had gestational diabetes. Twenty women will wear the CGM for 10 days at 6-8 weeks after giving b…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists launch massive tissue collection to unlock secrets of head and neck diseases
Knowledge-focused Recruiting nowThis study aims to create a large collection of tissue samples from people with head and neck disorders, such as hearing loss, mouth diseases, and throat cancers. Researchers will use leftover surgical tissue and additional samples like blood, saliva, and cheek swabs to study the…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists launch major effort to unlock secrets of rare stomach cancer
Knowledge-focused Recruiting nowThis study follows 400 people aged 6 and older who have a rare stomach cancer called GIST. Researchers will collect tumor tissue during surgery and study it in the lab to learn more about the disease. Participants are monitored every 6 to 12 months for up to 10 years before surge…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists seek cancer samples to unlock immune secrets
Knowledge-focused Recruiting nowThis study collects blood and tumor samples from people with gastrointestinal cancers, such as stomach, liver, or colon cancer. Researchers want to learn how the immune system responds to these cancers. Participants give samples over several visits but receive no treatment as par…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists dive deep into endocrine tumors to unlock molecular secrets
Knowledge-focused Recruiting nowThis study enrolls people with endocrine tumors (such as thyroid, parathyroid, adrenal, or pancreatic tumors) who are scheduled for surgery or biopsy. Researchers collect samples of the tumor, nearby healthy tissue, blood, and urine to analyze genetic and molecular changes. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Why do people with IBD face higher heart risks? 600-Patient study aims to find out
Knowledge-focused Recruiting nowPeople with inflammatory bowel diseases like Crohn's disease and ulcerative colitis often face a higher risk of heart attacks, strokes, and other cardiovascular problems, but standard risk calculators may not capture that danger accurately. This observational study follows 600 pa…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
No treatment, just samples: new study aims to understand cancer immunity
Knowledge-focused Recruiting nowThis study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Scientists try to personalize heated chemo for stomach cancers
Knowledge-focused Recruiting nowThis study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 08:00 UTC
-
Gut bacteria clues: new stool test may spot IBS triggers
Knowledge-focused Recruiting nowThis study looks at the gut bacteria of 100 people with irritable bowel syndrome (IBS) to see if a stool test can help diagnose the condition. Half will follow a low-FODMAP diet, a common but restrictive eating plan. Researchers will compare the bacteria and symptoms between the …
Sponsor: Weizmann Institute of Science • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
New recovery plan for Kids' appendix surgery shows promise
Knowledge-focused Recruiting nowThis study tests a 20-step recovery plan (ERAS) for children aged 5-18 having laparoscopic appendix surgery. The goal is to see if the plan can be followed closely and safely in a hospital. Researchers will track how well the steps are followed and check for any major problems or…
Sponsor: Ahmet Burak Doğan, MD • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Teen diabetes risk linked to immune cells, new study suggests
Knowledge-focused Recruiting nowThis study looks at how certain immune cells, called meta-inflammatory monocytes, along with body composition and diet, may contribute to insulin resistance in adolescents. Researchers will collect blood samples and health information from 175 teens aged 14-18, including those wi…
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
AI takes on cancer experts: who makes better treatment plans?
Knowledge-focused Recruiting nowThis study will compare treatment recommendations made by a large language model (AI) with those made by a team of cancer experts for 180 people with rectal cancer. The AI will analyze de-identified patient information and suggest a treatment plan. The goal is to see how often th…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious liver disease
Knowledge-focused Recruiting nowThis study is observing 400 people aged 12 and older who have noncirrhotic portal hypertension (NCPH) or are at risk for it. NCPH is a liver condition that increases blood pressure in the liver's blood vessels without causing cirrhosis, and often has no early symptoms. Researcher…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Hidden spread: colon cancer's quiet path to the stomach's blood supply
Knowledge-focused Recruiting nowResearchers want to know how often colon cancer located at or near the hepatic flexure spreads to a fatty tissue called the right gastroepiploic mesentery. They will perform complete mesocolic excision, a standard colon cancer operation, and also remove this mesentery in 50 adult…
Sponsor: Jichao Qin • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Scientists investigate role of gut microbes in healing digestive leaks
Knowledge-focused Recruiting nowThis study looks at how bacteria in the gut (the microbiome) influence healing of leaks in the esophagus or stomach. Researchers will collect tissue and fluid samples from 50 adults during routine procedures to analyze microbial changes and the body's response. The goal is to und…
Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Massive european study aims to redefine success in liver transplants
Knowledge-focused Recruiting nowThis study is collecting information from 10,000 liver transplant patients across Europe to create a new, up-to-date reference for what good outcomes look like when using machine perfusion (a technique that keeps donated livers healthier before transplant). The goal is to help do…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Massive study to map Real-World GEP-NET care
Knowledge-focused Recruiting nowThis study will analyze medical records of over 4,000 people newly diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NET) in the U.S. Researchers aim to understand which treatments are used, in what order, and how long patients stay on them. The goal is to describe…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Scientists hunt for genetic clues in lung and esophageal cancers
Knowledge-focused Recruiting nowThis study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
10,000 volunteers needed to unlock allergy mysteries
Knowledge-focused Recruiting nowThis study aims to collect blood, nasal fluid, skin cells, urine, and medical data from 10,000 people aged 3 to 100 with allergies, asthma, eczema, or sinus issues. Participants will have up to 3 years of follow-up visits and questionnaires. The goal is to create a large reposito…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Massive review of 4,000 liver cancer patients aims to uncover regional trends
Knowledge-focused Recruiting nowThis study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and wh…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Rectal and anal cancer carry a hidden social burden. researchers want to measure it.
Knowledge-focused Recruiting nowPeople with rectal and anal cancer often face social stigma tied to bowel symptoms, exams, and ostomy use. Researchers want to understand how that stigma relates to personality, emotional traits, and quality of life. The study asks 148 adults receiving chemoradiation for locally …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Can a quieter operating room mean safer surgery?
Knowledge-focused Recruiting nowORCHESTRA is an observational study of adults having colorectal or anal surgery at one hospital. Trained observers record naturally occurring distractions during routine operations, such as phone calls, conversations, and equipment problems. After each operation, the surgeon repo…
Sponsor: National and Kapodistrian University of Athens • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
New study aims to catch pancreatic cancer early in High-Risk groups
Knowledge-focused Recruiting nowThis study is for people at high risk of pancreatic cancer, such as those with a strong family history or certain genetic conditions. Researchers will use MRI and endoscopic ultrasound to screen participants regularly and see which method works best. The goal is to detect cancer …
Sponsor: Masaryk Memorial Cancer Institute • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
AI and blood tests aim to catch pancreatic cancer earlier
Knowledge-focused Recruiting nowThis study tests a new screening program for people aged 50 to 85 who have recently developed diabetes and are at high risk for pancreatic cancer. Participants will receive repeated AI-enhanced CT scans and blood draws over time to see if these tools can spot cancer earlier than …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Can fasting lower pancreatic cancer risk? small study aims to find out
Knowledge-focused Recruiting nowThis study will test whether intermittent fasting (eating only during an 8-hour window each day) is safe and doable for 20 people at high risk for pancreatic cancer. Researchers will also check if this eating pattern changes certain markers in the body linked to cancer risk. The …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Liver function and drug breakdown: a new study on mirdametinib
Knowledge-focused Recruiting nowThis study looks at how the drug mirdametinib is absorbed and removed from the body in people with moderate or severe liver problems compared to those with normal liver function. It involves 32 adults and is for research only, not to treat any condition. The goal is to understand…
Phase 1 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
New study tracks Finerenone's impact on kidney risk in diabetic patients
Knowledge-focused Recruiting nowThis study will follow 500 adults with chronic kidney disease and type 2 diabetes who are taking finerenone, a drug that helps protect the kidneys and heart. Researchers want to see if a tool called the Klinrisk score, which estimates the risk of kidney disease getting worse, imp…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Small study aims to predict how Barrett's esophagus responds to heat therapy
Knowledge-focused Recruiting nowThis study looks at how the esophagus changes in people with a precancerous condition called Barrett's esophagus who are getting a treatment called radiofrequency ablation (RFA). Researchers will use two special devices during routine endoscopies to measure the tightness and heal…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
New blood test could reduce unnecessary transfusions in liver shunt patients
Knowledge-focused Recruiting nowThis study looks at whether a special blood test called thrombelastography can help doctors decide when to give blood products to people with liver cirrhosis who are getting a TIPS shunt. The goal is to see if this test reduces the amount of blood products used and prevents bleed…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Could gut bacteria drive muscle wasting in cirrhosis?
Knowledge-focused Recruiting nowMany people with liver cirrhosis lose muscle, a condition called sarcopenia that raises the risk of complications and death. Researchers suspect that changes in gut bacteria play a role because the microbiome helps the body absorb and use nutrients. This study follows 120 hospita…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Tailored muscle cuts for swallowing disorders: a precision medicine trial
Knowledge-focused Recruiting nowThis study observes how doctors decide the length of the muscle cut during POEM surgery for people with swallowing disorders like achalasia. Researchers will follow 200 adults for 2 years, tracking symptoms and whether retreatment is needed. The goal is to see if tailoring the su…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Can we predict how older cancer patients fare after surgery?
Knowledge-focused Recruiting nowThis study follows 327 patients aged 65 and older who have surgery to remove gastrointestinal cancer. Researchers want to find out what factors predict whether patients will have a decline in physical function or quality of life one year later, and how they do over five years. Th…
Sponsor: Hospital Universitario Mayor Méderi • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Austrian biobank aims to map muscle loss in liver and gut disease
Knowledge-focused Recruiting nowResearchers at the Medical University of Graz are setting up a biobanking study to study sarcopenia, or muscle loss, in people with liver cirrhosis and chronic inflammatory bowel disease. They plan to enroll 1,000 adults who have a routine CT or MRI scan, collecting clinical data…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
500 patients enrolled in Largest-Ever study of brain tapeworm outcomes
Knowledge-focused Recruiting nowThis study follows 500 people with neurocysticercosis, a brain infection caused by the pork tapeworm. Participants receive standard antiparasitic drugs and anti-inflammatories. Researchers will track their health over many years to understand what factors lead to better or worse …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Massive study aims to unlock secrets of food allergies
Knowledge-focused Recruiting nowThis study looks at the causes and effects of food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will collect blood, skin, and genetic samples from up to 1,800 people over many years. The goal is to find biomarkers and pathways that explai…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Can new blood and imaging tests predict colon cancer liver spread?
Knowledge-focused Recruiting nowThis pilot study aims to develop new ways to diagnose colon cancer and predict if it will spread to the liver. Researchers will collect blood and liver tissue samples from 51 patients undergoing surgery for colon cancer or benign colon growths. The goal is to find biomarkers that…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
New study seeks clues to liver damage after fontan surgery
Knowledge-focused Recruiting nowThis study looks at why some adults who had the Fontan procedure as children develop serious liver scarring. Researchers will use blood tests, imaging, and liver biopsies to track changes and find early markers of disease. The goal is to better understand the process and pave the…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
New study to reveal hidden pancreatic issues in alagille syndrome patients after transplant
Knowledge-focused Recruiting nowThis study aims to find out how often exocrine pancreatic insufficiency (EPI) occurs in people with Alagille syndrome who have had a liver transplant. About 30 participants aged 7 to 50 will eat a high-fat diet and collect stool samples for lab testing. The results will help doct…
Sponsor: Digestive Care, Inc. • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
NIH launches study to uncover genetic roots of Hormone-Driven high blood pressure in black communities
Knowledge-focused Recruiting nowThis study aims to find the genetic causes of primary aldosteronism, a condition where adrenal tumors cause high blood pressure, in Black individuals. Researchers will enroll 1150 participants, including those with difficult-to-control blood pressure or known primary aldosteronis…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
New study aims to uncover hidden risks of kidney disease in american indians
Knowledge-focused Recruiting nowThis study follows 500 American Indian adults with early kidney disease to learn how their condition progresses and what factors affect heart health. Researchers will measure kidney function and track heart events like heart attacks and strokes. The goal is to fill knowledge gaps…
Sponsor: University of New Mexico • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Smartwatches may spot IBD flares before symptoms start
Knowledge-focused Recruiting nowThis study explores whether changes in heart rate, sleep, and activity measured by a person's own smartwatch can predict flare-ups in inflammatory bowel disease (IBD). Six hundred adults with Crohn's disease or ulcerative colitis who already own a compatible device will participa…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Diabetes and vitamin c loss: scientists launch major study to solve the mystery
Knowledge-focused Recruiting nowThis study aims to find out why people with diabetes often have lower vitamin C levels in their blood. Researchers will measure vitamin C in blood, urine, and cells from 5,000 adults with and without diabetes. They will also look at genes that control vitamin C transport. The goa…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Family study aims to unlock secrets of rare gut cancer
Knowledge-focused Recruiting nowThis study looks at families where multiple members have had small bowel carcinoid tumors, a rare and slow-growing cancer. Researchers want to learn how the disease develops, improve early detection, and find the genes that may cause it. Participants, including those with and wit…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
NIH launches major study to uncover hidden causes of dangerous low blood sugar
Knowledge-focused Recruiting nowThis study aims to better understand why some people experience dangerously low blood sugar (hypoglycemia), especially after fasting. Researchers will admit 1,500 adults to the NIH Clinical Center for controlled fasting and a series of blood tests to measure insulin and other fac…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Scientists launch deep dive into rare bleeding and lung disease
Knowledge-focused Recruiting nowThis study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Massive PSC study aims to create blueprint for faster drug trials
Knowledge-focused Recruiting nowThis study is gathering health information from 2,000 adults with primary sclerosing cholangitis (PSC) to build a real-world data comparator group. The goal is to help design and run future drug trials more efficiently by providing a control group from real patient experiences. P…
Sponsor: PSC Partners Seeking a Cure • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Liver function may change how new lung drug works
Knowledge-focused Recruiting nowThis study looks at how a single dose of the experimental drug BI 1291583 behaves in the blood of people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take part, divided into groups based o…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
New study aims to outsmart hepatitis b drug resistance
Knowledge-focused Recruiting nowThis study looks at how the hepatitis B virus changes over time in people taking antiviral drugs. Researchers will analyze blood samples from 700 adults in Turkey to see if the virus becomes resistant to treatment. The goal is to help doctors choose the best medications for each …
Sponsor: Yaşar Bayındır, MD • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Yale study asks: can tight blood sugar control rewind brain glucose handling in diabetes?
Knowledge-focused Recruiting nowResearchers at Yale are studying how high blood sugar affects the brain in people with poorly controlled type 2 diabetes. The trial tests whether intensive diabetes management, including nutrition counseling and medication adjustments, can improve the brain's ability to transport…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
DNA hunt aims to explain why IBD strikes some populations harder
Knowledge-focused Recruiting nowResearchers at Mount Sinai Hospital in Canada are studying how genes and environment contribute to inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The study plans to enroll about 150 people, both those with IBD and healthy volunteers, who provide a b…
Sponsor: Mount Sinai Hospital, Canada • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Why do so many canadian kids get IBD? a nationwide study hunts for answers
Knowledge-focused Recruiting nowResearchers across Canada are following 2,400 children and teens who have just been diagnosed with Crohn's disease, ulcerative colitis, or undefined inflammatory bowel disease. The study collects genetic, environmental, and microbiome information to understand why IBD develops so…
Sponsor: The Hospital for Sick Children • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
New device for rectal cancer under the microscope
Knowledge-focused Recruiting nowThis study is collecting information from up to 999 people with rectal cancer who are treated with a special device called the MAASTRO HDR applicator. The goal is to learn how well it works and what side effects it causes, so doctors can improve future treatments. Participants wi…
Sponsor: Maastricht Radiation Oncology • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
New study tests if coaching can slow kidney disease in diabetics
Knowledge-focused Recruiting nowThis pilot study tests a program that provides education, motivation, and social support to adults with diabetes and early-stage chronic kidney disease (CKD). The goal is to see if the program is practical and helps patients stay motivated, learn about kidney disease, and use sup…
Sponsor: University of Illinois at Chicago • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Safer syringe program aims to cut infections in drug users worldwide
Knowledge-focused Recruiting nowThis study looks at whether giving out special syringes with less leftover space (low dead-space) can help reduce the spread of HIV and hepatitis among people who inject drugs. Researchers will talk with participants and track their health in several countries. The goal is to fin…
Sponsor: Médecins du Monde • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Scientists map hidden edges of rectal tumors to sharpen radiation aim
Knowledge-focused Recruiting nowResearchers want to know how far microscopic rectal cancer cells spread beyond the visible tumor. The study enrolls 50 adults with rectal adenocarcinoma who are scheduled for surgery after radiation or chemoradiotherapy. Doctors use 3D endorectal ultrasound, rectoscopy, and patho…
Sponsor: Maastricht Radiation Oncology • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Scientists hunt for cancer clues in blood, urine, and bone marrow
Knowledge-focused Recruiting nowThis study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…
Sponsor: University of Missouri-Columbia • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
New study investigates if smart insulin pumps reduce disordered eating in diabetes
Knowledge-focused Recruiting nowThis study looks at whether newer automated insulin delivery systems help people with type 1 diabetes have healthier eating behaviors. Researchers will survey over 100 youth and adults across Canada about their eating habits and blood sugar control. The goal is to understand if t…
Sponsor: McGill University • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Why does the same meal spike one Person's blood sugar and not another?
Knowledge-focused Recruiting nowResearchers at the German Institute of Human Nutrition are studying why blood sugar responses to food differ so much from person to person. The LIME study follows 300 adults who are overweight or obese, including people with prediabetes, people with type 2 diabetes, and people wi…
Sponsor: German Institute of Human Nutrition • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Gut chemical serotonin under scrutiny in IBD research
Knowledge-focused Recruiting nowResearchers at McMaster University are studying how serotonin signaling differs in people with inflammatory bowel disease (IBD) compared with healthy controls. The trial enrolls about 60 participants, including people with Crohn's disease or ulcerative colitis and people without …
Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Mapping Real-World care for stomach cancer in greece
Knowledge-focused Recruiting nowThis observational study tracks how patients with stage II to IVB gastric or gastroesophageal junction cancer are actually treated in routine clinical practice across Greece. Researchers will collect data on patient characteristics, treatment choices, timing of therapies, and bio…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Liver biopsies reveal Fat-Busting secrets in alcohol detox
Knowledge-focused Recruiting nowThis study looks at how the liver processes fat in people with alcohol use disorder who are quitting drinking. Researchers will take two small liver samples—one early in detox and one after four weeks—to compare gene activity. The goal is to understand how the liver clears fat wh…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
What happens when your genes reveal a surprise? new study seeks answers.
Knowledge-focused Recruiting nowThis study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
New national registry aims to unlock secrets of rare childhood liver diseases
Knowledge-focused Recruiting nowThis study creates a Canadian registry for children under 18 with Alagille syndrome or genetic intrahepatic cholestasis, rare liver conditions that cause bile buildup. Researchers will collect health data from medical records over time to understand how these diseases progress an…
Sponsor: Children's Hospital of Eastern Ontario • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Mapping the hidden pressure points that threaten diabetic feet
Knowledge-focused Recruiting nowResearchers at Nanyang Technological University are studying how pressure shifts across the bottom of the foot when people with type 2 diabetes walk after losing part of the forefoot, such as the fifth toe. The study enrolls 70 adults with a healed lateral forefoot amputation who…
Sponsor: Nanyang Technological University • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
NCI opens screening study for experimental cell therapies in multiple cancers
Knowledge-focused Recruiting nowThis study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Your smartwatch could predict blood sugar crashes before they happen
Knowledge-focused Recruiting nowThis study will test whether combining continuous glucose monitor (CGM) data with information from a smartwatch and a phone app (like meals and activity) can better predict blood sugar levels in people with type 2 diabetes. Thirty-six adults will wear a CGM and smartwatch and log…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
New study explores why cancer patients lose their appetite
Knowledge-focused Recruiting nowThis study looks at how cancer and its treatments change a person's sense of taste and smell, and how that affects their eating and nutrition. Researchers will follow 306 people newly diagnosed with cancer of the mouth, throat, colon, or liver. They will use questionnaires, taste…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Scientists launch major study to uncover secrets of insulin resistance
Knowledge-focused Recruiting nowThis study aims to learn more about insulin resistance and diabetes by collecting blood and skin samples from up to 1,200 participants, including patients with severe insulin resistance and their family members. Researchers will study genetics and how insulin works in the body to…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Could a COVID shot boost cancer treatment? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether getting an mRNA COVID-19 vaccine within three months before starting immunotherapy improves outcomes for people with liver cancer. Researchers will review medical records of 200 patients in Austria to compare response rates, survival, and side effects …
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Liver biobank aims to unlock secrets of hepatitis and fatty liver disease
Knowledge-focused Recruiting nowResearchers at the State University of New York at Buffalo are creating a biorepository, a collection of blood and liver tissue samples, from people with and without liver diseases. The goal is to give future scientists high-quality specimens to study how conditions like hepatiti…
Sponsor: State University of New York at Buffalo • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC